B-cell	B-cell_type
proliferation	O
and	O
induction	O
of	O
early	O
G1-regulating	B-protein
proteins	I-protein
by	O
Epstein-Barr	O
virus	O
mutants	O
conditional	O
for	O
EBNA2	B-protein
.	O

Infection	O
of	O
primary	B-cell_type
B-lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
leads	O
to	O
growth	O
transformation	O
of	O
these	O
B-cells	B-cell_type
in	O
vitro	O
.	O

EBV	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	B-protein
)	O
,	O
one	O
of	O
the	O
first	O
genes	O
expressed	O
after	O
EBV	O
infection	O
of	O
B-cells	B-cell_type
,	O
is	O
a	O
transcriptional	O
activator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
and	O
is	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
virus	O
.	O

We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B-protein
as	O
chimeric	B-protein
fusion	I-protein
protein	I-protein
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O

Growth	O
transformation	O
of	O
primary	B-cell_type
normal	I-cell_type
B-cells	I-cell_type
by	O
mutant	O
virus	O
resulted	O
in	O
estrogen-dependent	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
chimeric	O
EBNA2	B-protein
protein	I-protein
.	O

In	O
the	O
absence	O
of	O
estrogen	O
about	O
half	O
of	O
the	O
cells	O
enter	O
a	O
quiescent	O
non-proliferative	O
state	O
whereas	O
the	O
others	O
die	O
by	O
apoptosis	O
.	O

EBNA2	B-protein
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation	O
.	O

Growth	O
arrest	O
occurred	O
at	O
G1	O
and	O
G2	O
stages	O
of	O
the	O
cell	O
cycle	O
,	O
indicating	O
that	O
functional	O
EBNA2	B-protein
is	O
required	O
at	O
different	O
restriction	O
points	O
of	O
the	O
cell	O
cycle	O
.	O

Growth	O
arrest	O
is	O
reversible	O
for	O
G1/G0	B-cell_type
cells	I-cell_type
as	O
indicated	O
by	O
the	O
sequential	O
accumulation	O
and	O
modification	O
of	O
cell	B-protein
cycle	I-protein
regulating	I-protein
proteins	I-protein
.	O

EBV	O
induces	O
the	O
same	O
cell	O
cycle	O
regulating	O
proteins	O
as	O
polyclonal	O
stimuli	O
in	O
primary	O
B-cells	B-cell_type
.	O

These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B-cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T-cell	O
signals	O
and	O
growth	B-protein
factors	I-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.14	NULL
no.1	NULL
pp.88-96	NULL
,	NULL
1995	NULL
B-cell	NULL
proliferation	NULL
and	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-regulating	NULL
proteins	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
mutants	NULL
conditional	NULL
for	NULL
EBNA2	NULL
Bettina	NULL
Kempkes	NULL
,	NULL
Dimitry	NULL
Spitkovsky	NULL
'	NULL
,	NULL
Pidder	NULL
Jansen-Diirr	NULL
'	NULL
,	NULL
Joachim	NULL
W.Ellwart2	NULL
,	NULL
Elisabeth	NULL
Kremmer®	NULL
,	NULL
Henri-Jacques	NULL
Delecluse*	NULL
,	NULL
Christine	NULL
Rottenberger	NULL
,	NULL
Georg	NULL
W.Bornkamm*	NULL
``	NULL
and	NULL
Wolfgang	NULL
Hammerschmidt	NULL
Institut	NULL
fiir	NULL
Klinische	NULL
Molekularbiologie	NULL
und	NULL
Tumorgenetik	NULL
,	NULL
``	NULL
Institut	NULL
fiir	NULL
Experimentelle	NULL
Institut	NULL
fiir	NULL
Immunologie	NULL
,	NULL
Hamatologikum	NULL
der	NULL
GSF	NULL
,	NULL
MarchioninistraBe	NULL
25	NULL
,	NULL
D-81377	NULL
Miinchen	NULL
and	NULL
'Deutsches	NULL
Krebsforschungszentrum	NULL
,	NULL
Angewandte	NULL
Tumorvirologie	NULL
,	NULL
D-69120	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
*Present	NULL
address	NULL
:	NULL
Hopital	NULL
E.Herriot	NULL
,	NULL
Place	NULL
d	NULL
'	NULL
Arsonval	NULL
,	NULL
F-69	NULL
Lyon	NULL
,	NULL
France	NULL
Corresponding	NULL
author	NULL
Communicated	NULL
by	NULL
T.Lindaht	NULL
Infection	NULL
of	NULL
primary	NULL
B-lymphocytes	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
leads	NULL
to	NULL
growth	NULL
transformation	NULL
of	NULL
these	NULL
B-cells	NULL
in	NULL
vitro	NULL
.	NULL

EBV	NULL
nuclear	NULL
antigen	NULL
2	NULL
(	NULL
EBNA2	NULL
)	NULL
,	NULL
one	NULL
of	NULL
the	NULL
first	NULL
genes	NULL
expressed	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
B-cells	NULL
,	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
transforming	NULL
potential	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

We	NULL
generated	NULL
conditional	NULL
EBV	NULL
mutants	NULL
by	NULL
expressing	NULL
EBNAZ	NULL
as	NULL
chimeric	NULL
fusion	NULL
protein	NULL
with	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
on	NULL
the	NULL
genetic	NULL
background	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

Growth	NULL
transformation	NULL
of	NULL
primary	NULL
normal	NULL
B-cells	NULL
by	NULL
mutant	NULL
virus	NULL
resulted	NULL
in	NULL
estrogen-dependent	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
chimeric	NULL
EBNA2	NULL
protein	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
estrogen	NULL
about	NULL
half	NULL
of	NULL
the	NULL
cells	NULL
enter	NULL
a	NULL
quiescent	NULL
non-proliferative	NULL
state	NULL
whereas	NULL
the	NULL
others	NULL
die	NULL
by	NULL
apoptosis	NULL
.	NULL

EBNA2	NULL
is	NULL
thus	NULL
required	NULL
not	NULL
only	NULL
for	NULL
initiation	NULL
but	NULL
also	NULL
for	NULL
maintenance	NULL
of	NULL
transformation	NULL
.	NULL

Growth	NULL
arrest	NULL
occurred	NULL
at	NULL
G	NULL
,	NULL
and	NULL
G	NULL
;	NULL
stages	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
indicating	NULL
that	NULL
functional	NULL
EBNA2	NULL
is	NULL
required	NULL
at	NULL
different	NULL
restriction	NULL
points	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Growth	NULL
arrest	NULL
is	NULL
reversible	NULL
for	NULL
G/G	NULL
,	NULL
cells	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
sequential	NULL
accumulation	NULL
and	NULL
modification	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
.	NULL

EBV	NULL
induces	NULL
the	NULL
same	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
as	NULL
polyclonal	NULL
stimuli	NULL
in	NULL
primary	NULL
B-cells	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
EBV	NULL
is	NULL
using	NULL
a	NULL
common	NULL
pathway	NULL
for	NULL
B-cell	NULL
activation	NULL
bypassing	NULL
the	NULL
requirement	NULL
for	NULL
antigen	NULL
,	NULL
T-cell	NULL
signals	NULL
and	NULL
growth	NULL
factors	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
Epstein-Barr	NULL
virus/conditional	NULL
EBNA2	NULL
estrogen	NULL
receptor/cell	NULL
cycle/CD40	NULL
Introduction	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
ubiquitous	NULL
human	NULL
herpes	NULL
virus	NULL
with	NULL
a	NULL
linear	NULL
viral	NULL
genome	NULL
of	NULL
~175	NULL
kb	NULL
.	NULL

The	NULL
virus	NULL
has	NULL
a	NULL
dual	NULL
tropism	NULL
for	NULL
B-lymphocytes	NULL
and	NULL
epithelial	NULL
cells	NULL
.	NULL

88	NULL
Infection	NULL
of	NULL
B-cells	NULL
is	NULL
usually	NULL
non-productive	NULL
whereas	NULL
virus	NULL
replication	NULL
takes	NULL
place	NULL
in	NULL
epithelial	NULL
cells	NULL
of	NULL
the	NULL
nasopharyngeal	NULL
cavity	NULL
and	NULL
leads	NULL
to	NULL
synthesis	NULL
of	NULL
infectious	NULL
progeny	NULL
which	NULL
are	NULL
excreted	NULL
in	NULL
the	NULL
saliva	NULL
.	NULL

Primary	NULL
infection	NULL
with	NULL
EBV	NULL
is	NULL
usually	NULL
silent	NULL
,	NULL
but	NULL
may	NULL
give	NULL
rise	NULL
to	NULL
infectious	NULL
mononucleosis	NULL
,	NULL
a	NULL
self-limiting	NULL
lymphoprolifera-tive	NULL
disease	NULL
.	NULL

After	NULL
primary	NULL
infection	NULL
the	NULL
virus	NULL
persists	NULL
lifelong	NULL
in	NULL
the	NULL
body	NULL
in	NULL
the	NULL
lymphoid	NULL
compartment	NULL
in	NULL
a	NULL
latent	NULL
,	NULL
still	NULL
poorly	NULL
defined	NULL
state	NULL
.	NULL

Infection	NULL
of	NULL
B-lymphocytes	NULL
with	NULL
EBV	NULL
in	NULL
vitro	NULL
leads	NULL
to	NULL
unlimited	NULL
proliferation	NULL
of	NULL
infected	NULL
cells	NULL
,	NULL
a	NULL
process	NULL
called	NULL
transformation	NULL
or	NULL
immortalization	NULL
.	NULL

In	NULL
EBV-transformed	NULL
cells	NULL
the	NULL
viral	NULL
genome	NULL
is	NULL
maintained	NULL
in	NULL
multiple	NULL
episomal	NULL
copies	NULL
.	NULL

EBV	NULL
drives	NULL
proliferation	NULL
of	NULL
infected	NULL
B-cells	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
limited	NULL
set	NULL
of	NULL
viral	NULL
genes	NULL
coding	NULL
for	NULL
six	NULL
nuclear	NULL
antigens	NULL
(	NULL
EBNA1I	NULL
,	NULL
2	NULL
,	NULL
3A	NULL
,	NULL
3B	NULL
,	NULL
3C	NULL
,	NULL
EBNA-LP	NULL
)	NULL
,	NULL
three	NULL
membrane	NULL
antigens	NULL
(	NULL
LMP1	NULL
,	NULL
LMP2A	NULL
and	NULL
LMP2B	NULL
)	NULL
,	NULL
and	NULL
two	NULL
small	NULL
RNA	NULL
polymerase	NULL
III	NULL
transcripts	NULL
,	NULL
the	NULL
EBERs	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Miller	NULL
1990	NULL
;	NULL
Kieff	NULL
and	NULL
Liebowitz	NULL
,	NULL
1990	NULL
;	NULL
Rogers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
for	NULL
details	NULL
see	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Five	NULL
of	NULL
these	NULL
genes	NULL
(	NULL
EBNA1	NULL
,	NULL
2	NULL
,	NULL
3A	NULL
,	NULL
3C	NULL
and	NULL
LMP	NULL
1	NULL
)	NULL
are	NULL
required	NULL
for	NULL
initiation	NULL
of	NULL
transformation	NULL
(	NULL
Hammerschmidt	NULL
and	NULL
Sugden	NULL
,	NULL
1989	NULL
;	NULL
Cohen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Kaye	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Tomkinson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
but	NULL
they	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
.	NULL

The	NULL
minimal	NULL
set	NULL
of	NULL
viral	NULL
genes	NULL
required	NULL
for	NULL
initiation	NULL
of	NULL
transformation	NULL
is	NULL
still	NULL
unknown	NULL
.	NULL

EBNA2	NULL
is	NULL
one	NULL
of	NULL
the	NULL
first	NULL
genes	NULL
expressed	NULL
after	NULL
EBV	NULL
infection	NULL
of	NULL
B-cells	NULL
(	NULL
Allday	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

It	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
transforming	NULL
potential	NULL
of	NULL
the	NULL
virus	NULL
.	NULL

EBNA2	NULL
modulates	NULL
host	NULL
cell	NULL
gene	NULL
expression	NULL
by	NULL
induction	NULL
of	NULL
cellular	NULL
antigens	NULL
CD21	NULL
and	NULL
CD23	NULL
(	NULL
Calender	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Cordier	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
the	NULL
proto-oncogene	NULL
c-fgr	NULL
(	NULL
Knutson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

EBNA2	NULL
activates	NULL
transcription	NULL
of	NULL
the	NULL
genes	NULL
of	NULL
the	NULL
three	NULL
virally	NULL
encoded	NULL
membrane	NULL
antigens	NULL
(	NULL
Abbot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Fahraeus	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
one	NULL
of	NULL
the	NULL
promoters	NULL
(	NULL
Cp	NULL
)	NULL
driving	NULL
transcription	NULL
of	NULL
all	NULL
nuclear	NULL
antigens	NULL
including	NULL
EBNAZ	NULL
is	NULL
activated	NULL
by	NULL
EBNA2	NULL
(	NULL
Sung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
,	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
see	NULL
Figure	NULL
1B	NULL
for	NULL
details	NULL
)	NULL
.	NULL

EBNA2	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
DNA	NULL
directly	NULL
.	NULL

It	NULL
transactivates	NULL
the	NULL
LMP2A	NULL
and	NULL
C	NULL
promoter	NULL
through	NULL
binding	NULL
to	NULL
a	NULL
cellular	NULL
protein	NULL
which	NULL
binds	NULL
to	NULL
specific	NULL
sequence	NULL
elements	NULL
(	NULL
EBNA2	NULL
responsive	NULL
element	NULL
,	NULL
EBNA2RE	NULL
)	NULL
and	NULL
mediates	NULL
the	NULL
EBNA2	NULL
response	NULL
(	NULL
Ling	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
cellular	NULL
protein	NULL
has	NULL
recently	NULL
been	NULL
identified	NULL
as	NULL
RBP-Jx	NULL
(	NULL
Henkel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
personal	NULL
communication	NULL
)	NULL
,	NULL
a	NULL
ubiquitously	NULL
expressed	NULL
and	NULL
highly	NULL
conserved	NULL
protein	NULL
which	NULL
was	NULL
characterized	NULL
and	NULL
cloned	NULL
by	NULL
virtue	NULL
of	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
recombination	NULL
signal	NULL
of	NULL
the	NULL
murine	NULL
immunoglobulin	NULL
x	NULL
joining	NULL
region	NULL
(	NULL
Matsunami	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Although	NULL
detailed	NULL
information	NULL
is	NULL
accumulating	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
in	NULL
cells	NULL
transformed	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
vitro	NULL
,	NULL
our	NULL
knowledge	NULL
on	NULL
the	NULL
initial	NULL
events	NULL
and	NULL
the	NULL
pathway	NULL
activated	NULL
by	NULL
the	NULL
virus	NULL
lags	NULL
far	NULL
behind	NULL
for	NULL
a	NULL
number	NULL
of	NULL
reasons	NULL
.	NULL

First	NULL
,	NULL
transformation	NULL
of	NULL
a	NULL
B-cell	NULL
from	NULL
primary	NULL
infection	NULL
to	NULL
outgrowth	NULL
of	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
LCL	NULL
)	NULL
is	NULL
a	NULL
non-synchronous	NULL
process	NULL
which	NULL
takes	NULL
place	NULL
in	NULL
only	NULL
a	NULL
minority	NULL
of	NULL
cells	NULL
over	NULL
several	NULL
days	NULL
(	NULL
Chan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
difficult	NULL
to	NULL
assess	NULL
biochemically	NULL
the	NULL
order	NULL
of	NULL
events	NULL
and	NULL
to	NULL
draw	NULL
conclusions	NULL
about	NULL
their	NULL
causal	NULL
relationship	NULL
.	NULL

Secondly	NULL
,	NULL
growth	NULL
transformation	NULL
by	NULL
EBV	NULL
is	NULL
a	NULL
complex	NULL
process	NULL
.	NULL

It	NULL
involves	NULL
not	NULL
only	NULL
the	NULL
interplay	NULL
of	NULL
at	NULL
least	NULL
five	NULL
viral	NULL
genes	NULL
but	NULL
also	NULL
stimulation	NULL
of	NULL
the	NULL
target	NULL
cell	NULL
through	NULL
the	NULL
virus	NULL
receptor	NULL
(	NULL
Hutt-Fletcher	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

All	NULL
attempts	NULL
to	NULL
transform	NULL
primary	NULL
human	NULL
B-cells	NULL
by	NULL
transfection	NULL
of	NULL
intact	NULL
viral	NULL
DNA	NULL
or	NULL
viral	NULL
DNA	NULL
fragments	NULL
have	NULL
thus	NULL
been	NULL
unsuccessful	NULL
so	NULL
far	NULL
.	NULL

Thirdly	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
a	NULL
permissive	NULL
tissue	NULL
culture	NULL
system	NULL
for	NULL
propagation	NULL
of	NULL
the	NULL
virus	NULL
has	NULL
precluded	NULL
the	NULL
development	NULL
of	NULL
,	NULL
for	NULL
example	NULL
,	NULL
temperature-sensitive	NULL
mutants	NULL
in	NULL
viral	NULL
gene	NULL
functions	NULL
required	NULL
for	NULL
transformation	NULL
.	NULL

The	NULL
only	NULL
source	NULL
of	NULL
the	NULL
virus	NULL
so	NULL
far	NULL
are	NULL
EBV-carrying	NULL
lymphoid	NULL
cell	NULL
lines	NULL
in	NULL
which	NULL
a	NULL
small	NULL
and	NULL
variable	NULL
proportion	NULL
of	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
for	NULL
lytic	NULL
viral	NULL
replication	NULL
.	NULL

The	NULL
discovery	NULL
of	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
and	NULL
the	NULL
viral	NULL
packaging	NULL
signal	NULL
(	NULL
Hammerschmidt	NULL
and	NULL
Sugden	NULL
,	NULL
1988	NULL
)	NULL
has	NULL
opened	NULL
new	NULL
avenues	NULL
for	NULL
EBV	NULL
genetics	NULL
,	NULL
since	NULL
viral	NULL
sequences	NULL
modified	NULL
or	NULL
mutated	NULL
in	NULL
vitro	NULL
can	NULL
now	NULL
be	NULL
incorporated	NULL
into	NULL
infectious	NULL
virions	NULL
.	NULL

We	NULL
describe	NULL
here	NULL
the	NULL
development	NULL
of	NULL
an	NULL
EBV	NULL
mutant	NULL
which	NULL
can	NULL
transform	NULL
primary	NULL
resting	NULL
B-cells	NULL
in	NULL
a	NULL
reversible	NULL
fashion	NULL
.	NULL

This	NULL
mutant	NULL
allows	NULL
reconstitution	NULL
of	NULL
the	NULL
sequential	NULL
steps	NULL
of	NULL
B-cell	NULL
activation	NULL
following	NULL
primary	NULL
infection	NULL
and	NULL
provides	NULL
an	NULL
experimental	NULL
system	NULL
for	NULL
the	NULL
molecular	NULL
analysis	NULL
of	NULL
the	NULL
critical	NULL
events	NULL
.	NULL

Results	NULL
Primary	NULL
human	NULL
B-cells	NULL
can	NULL
be	NULL
transformed	NULL
by	NULL
EBV	NULL
encoding	NULL
EBNAZ-estrogen	NULL
receptor	NULL
fusion	NULL
proteins	NULL
Gene	NULL
fusion	NULL
of	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
a	NULL
steroid	NULL
receptor	NULL
to	NULL
an	NULL
unrelated	NULL
gene	NULL
can	NULL
render	NULL
the	NULL
chimeric	NULL
gene	NULL
product	NULL
hormone	NULL
inducible	NULL
(	NULL
Kumar	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Picard	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Eilers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Burk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Fusion	NULL
proteins	NULL
of	NULL
EBNA2Z	NULL
with	NULL
the	NULL
estrogen	NULL
receptor	NULL
(	NULL
ER	NULL
)	NULL
were	NULL
constructed	NULL
which	NULL
carry	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
either	NULL
at	NULL
the	NULL
C-	NULL
or	NULL
N-terminus	NULL
(	NULL
designated	NULL
EBNA2/ER	NULL
or	NULL
ER/EBNA2	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Conditional	NULL
function	NULL
of	NULL
both	NULL
constructs	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
hormone	NULL
was	NULL
verified	NULL
by	NULL
testing	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP	NULL
)	NULL
genes	NULL
which	NULL
are	NULL
known	NULL
target	NULL
genes	NULL
for	NULL
transcriptional	NULL
activation	NULL
by	NULL
EBNA2Z	NULL
.	NULL

Transactivation	NULL
of	NULL
these	NULL
genes	NULL
by	NULL
EBNA2/estrogen	NULL
receptor	NULL
chimeras	NULL
was	NULL
indeed	NULL
estrogen	NULL
dependent	NULL
(	NULL
Kempkes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

The	NULL
genes	NULL
encoding	NULL
the	NULL
conditional	NULL
EBNA2	NULL
mutants	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
mini-EBV	NULL
vector	NULL
(	NULL
Figure	NULL
1A	NULL
;	NULL
Hammerschmidt	NULL
and	NULL
Sugden	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

Mini-EBV	NULL
plasmids	NULL
carry	NULL
the	NULL
cis-acting	NULL
elements	NULL
which	NULL
are	NULL
essential	NULL
for	NULL
the	NULL
propagation	NULL
of	NULL
these	NULL
plasmids	NULL
in	NULL
all	NULL
phases	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
life	NULL
cycle	NULL
(	NULL
for	NULL
review	NULL
see	NULL
Kieff	NULL
and	NULL
Liebowitz	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

They	NULL
carry	NULL
the	NULL
plasmid	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
oriP	NULL
;	NULL
Yates	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
the	NULL
EBV	NULL
plasmids	NULL
in	NULL
target	NULL
cells	NULL
,	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
oriLyt	NULL
)	NULL
,	NULL
which	NULL
allows	NULL
replication	NULL
to	NULL
EBV	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-regulating	NULL
proteins	NULL
high	NULL
copy	NULL
number	NULL
as	NULL
large	NULL
concatemers	NULL
upon	NULL
induction	NULL
of	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
and	NULL
the	NULL
terminal	NULL
repeats	NULL
(	NULL
TR	NULL
)	NULL
,	NULL
which	NULL
permit	NULL
packaging	NULL
of	NULL
the	NULL
mini-EBV	NULL
plasmids	NULL
into	NULL
virions	NULL
(	NULL
Hammerschmidt	NULL
and	NULL
Sugden	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
non-transforming	NULL
P3HR	NULL
1	NULL
strain	NULL
of	NULL
EBV	NULL
,	NULL
in	NULL
which	NULL
the	NULL
EBNA2	NULL
open	NULL
reading	NULL
frame	NULL
has	NULL
been	NULL
deleted	NULL
(	NULL
Mueller-Lantzsch	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
served	NULL
as	NULL
a	NULL
helper	NULL
virus	NULL
for	NULL
amplification	NULL
and	NULL
packaging	NULL
of	NULL
these	NULL
mini-EBV	NULL
plasmids	NULL
.	NULL

P3HR1	NULL
(	NULL
HHS14	NULL
subclone	NULL
16	NULL
;	NULL
Rabson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
mini-EBV	NULL
plasmids	NULL
expressing	NULL
chimeric	NULL
or	NULL
wild-type	NULL
EBNA2	NULL
and	NULL
simultaneously	NULL
induced	NULL
for	NULL
lytic	NULL
cycle	NULL
replication	NULL
.	NULL

Supernatants	NULL
of	NULL
transfected	NULL
cells	NULL
containing	NULL
mini-EBVs	NULL
together	NULL
with	NULL
the	NULL
P3HR1	NULL
helper	NULL
virus	NULL
were	NULL
harvested	NULL
and	NULL
used	NULL
to	NULL
co-infect	NULL
primary	NULL
B-cells	NULL
,	NULL
which	NULL
were	NULL
cultivated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
estrogen	NULL
.	NULL

The	NULL
results	NULL
of	NULL
five	NULL
independent	NULL
experiments	NULL
compiled	NULL
in	NULL
Table	NULL
I	NULL
indicate	NULL
that	NULL
clones	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
were	NULL
more	NULL
easily	NULL
obtained	NULL
than	NULL
clones	NULL
expressing	NULL
ER/EBNA2	NULL
or	NULL
EBNA2/ER	NULL
.	NULL

Continuously	NULL
growing	NULL
clones	NULL
were	NULL
expanded	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

B-cells	NULL
transformed	NULL
by	NULL
EBNA2/estrogen	NULL
receptor	NULL
mutants	NULL
expressed	NULL
EBNA2	NULL
fusion	NULL
proteins	NULL
of	NULL
an	NULL
apparent	NULL
molecular	NULL
weight	NULL
of	NULL
120	NULL
kDa	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
86	NULL
kDa	NULL
protein	NULL
of	NULL
wild-type	NULL
EBNA2	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
the	NULL
wild-type	NULL
EBNA2	NULL
gene	NULL
was	NULL
confirmed	NULL
by	NULL
Southern	NULL
blot	NULL
analysis	NULL
in	NULL
EBNA2/estrogen	NULL
receptor-transformed	NULL
B-cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Of	NULL
eight	NULL
transformed	NULL
cell	NULL
clones	NULL
analysed	NULL
,	NULL
all	NULL
contained	NULL
mini-EBV	NULL
plasmids	NULL
expressing	NULL
the	NULL
chimeric	NULL
EBNAZ	NULL
protein	NULL
as	NULL
autonomously	NULL
replicating	NULL
plasmids	NULL
plus	NULL
the	NULL
P3HR1	NULL
viral	NULL
genome	NULL
,	NULL
thus	NULL
complementing	NULL
the	NULL
EBNA2	NULL
deletion	NULL
of	NULL
the	NULL
P3HR1	NULL
virus	NULL
in	NULL
trans	NULL
.	NULL

Lymphoblastoid	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
EBNA2/estrogen	NULL
receptor	NULL
fusion	NULL
proteins	NULL
proliferated	NULL
more	NULL
slowly	NULL
than	NULL
cells	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
.	NULL

Functional	NULL
EBNAZ	NULL
is	NULL
required	NULL
for	NULL
maintenance	NULL
of	NULL
B-cell	NULL
transformation	NULL
by	NULL
EBV	NULL
When	NULL
estrogen	NULL
was	NULL
withdrawn	NULL
from	NULL
the	NULL
culture	NULL
medium	NULL
of	NULL
the	NULL
EBNAZ2/estrogen	NULL
receptor-transformed	NULL
B-cells	NULL
,	NULL
phenotypic	NULL
changes	NULL
became	NULL
readily	NULL
apparent	NULL
.	NULL

The	NULL
cells	NULL
no	NULL
longer	NULL
formed	NULL
the	NULL
typical	NULL
tight	NULL
clumps	NULL
and	NULL
a	NULL
significant	NULL
proportion	NULL
of	NULL
the	NULL
cells	NULL
entered	NULL
apoptosis	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
fragmented	NULL
nuclei	NULL
after	NULL
acridine	NULL
orange	NULL
staining	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

All	NULL
B-cell	NULL
clones	NULL
expressing	NULL
either	NULL
of	NULL
the	NULL
two	NULL
EBNA2	NULL
derivatives	NULL
(	NULL
ER/EBNA2	NULL
and	NULL
EBNA2/ER	NULL
)	NULL
stopped	NULL
growing	NULL
but	NULL
retained	NULL
50	NULL
%	NULL
viability	NULL
of	NULL
the	NULL
starting	NULL
population	NULL
for	NULL
5	NULL
days	NULL
as	NULL
measured	NULL
by	NULL
MTT	NULL
conversion	NULL
(	NULL
Mosmann	NULL
,	NULL
1983	NULL
;	NULL
Figure	NULL
2A	NULL
)	NULL
and	NULL
propidium	NULL
iodide	NULL
and	NULL
trypan	NULL
blue	NULL
exclusion	NULL
assays	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
after	NULL
removal	NULL
of	NULL
estrogen	NULL
from	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

Growth	NULL
of	NULL
recombinant	NULL
LCL	NULL
clones	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
addition	NULL
or	NULL
removal	NULL
of	NULL
estrogen	NULL
.	NULL

DNA	NULL
synthesis	NULL
gradually	NULL
decreased	NULL
upon	NULL
withdrawal	NULL
of	NULL
estrogen	NULL
and	NULL
reached	NULL
basal	NULL
levels	NULL
on	NULL
days	NULL
4-5	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

Removal	NULL
of	NULL
estrogen	NULL
also	NULL
affected	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
ER/EBNA2	NULL
fusion	NULL
protein	NULL
.	NULL

ER/EBNA2	NULL
migrated	NULL
more	NULL
rapidly	NULL
and	NULL
homogeneously	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
hormone	NULL
,	NULL
indicating	NULL
that	NULL
switching	NULL
ER/EBNA2	NULL
function	NULL
on	NULL
and	NULL
off	NULL
is	NULL
associated	NULL
with	NULL
post-translational	NULL
modification	NULL
or	NULL
profound	NULL
changes	NULL
in	NULL
the	NULL
tertiary	NULL
structure	NULL
of	NULL
ER/	NULL
EBNA2Z	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
ER/EBNA2	NULL
fusion	NULL
protein	NULL
appeared	NULL
to	NULL
decrease	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
hormone	NULL
,	NULL
compatible	NULL
with	NULL
a	NULL
functional	NULL
role	NULL
of	NULL
EBNA2	NULL
in	NULL
positive	NULL
89	NULL
B.Kempkes	NULL
et	NULL
al	NULL
.	NULL

-\	NULL
mu-y	NULL
-y	NULL
--	NULL
*	NULL
I	NULL
m	NULL
g	NULL
cenas	NULL
Way	NULL
,	NULL
EBNASa	NULL
_-EBNA3b	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Strategy	NULL
for	NULL
expression	NULL
of	NULL
conditional	NULL
EBNA2	NULL
mutants	NULL
in	NULL
growth	NULL
transformed	NULL
B-cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Mini-EBV	NULL
plasmids	NULL
are	NULL
composed	NULL
of	NULL
cis-acting	NULL
elements	NULL
which	NULL
are	NULL
essential	NULL
for	NULL
the	NULL
propagation	NULL
of	NULL
these	NULL
plasmids	NULL
in	NULL
all	NULL
phases	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
life	NULL
cycle	NULL
.	NULL

They	NULL
carry	NULL
the	NULL
plasmid	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
oriP	NULL
)	NULL
necessary	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
the	NULL
EBV	NULL
plasmids	NULL
in	NULL
target	NULL
cells	NULL
,	NULL
the	NULL
lytic	NULL
origin	NULL
of	NULL
replication	NULL
(	NULL
oriLyt	NULL
)	NULL
,	NULL
which	NULL
allows	NULL
high	NULL
copy	NULL
number	NULL
amplification	NULL
upon	NULL
induction	NULL
of	NULL
lytic	NULL
replication	NULL
of	NULL
the	NULL
virus	NULL
,	NULL
and	NULL
the	NULL
terminal	NULL
repeats	NULL
(	NULL
TR	NULL
)	NULL
,	NULL
which	NULL
allow	NULL
packaging	NULL
of	NULL
the	NULL
mini-EBV	NULL
plasmids	NULL
into	NULL
virions	NULL
.	NULL

The	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
(	NULL
white	NULL
boxes	NULL
)	NULL
was	NULL
fused	NULL
to	NULL
either	NULL
the	NULL
C-	NULL
or	NULL
the	NULL
N-terminus	NULL
of	NULL
the	NULL
wild-type	NULL
EBNA2	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
black	NULL
boxes	NULL
)	NULL
yielding	NULL
the	NULL
EBNA2/ER	NULL
or	NULL
ER/EBNA2	NULL
mutants	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
EBNA2	NULL
expression	NULL
cassettes	NULL
are	NULL
flanked	NULL
by	NULL
EBV	NULL
sequences	NULL
,	NULL
the	NULL
BamHI	NULL
restriction	NULL
fragments	NULL
C	NULL
,	NULL
W	NULL
,	NULL
Y	NULL
and	NULL
H	NULL
of	NULL
the	NULL
EBV	NULL
genome	NULL
,	NULL
which	NULL
represent	NULL
in	NULL
part	NULL
the	NULL
genomic	NULL
organization	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
and	NULL
encompass	NULL
the	NULL
deletion	NULL
present	NULL
in	NULL
the	NULL
non-transforming	NULL
P3HR1	NULL
EBV	NULL
strain	NULL
(	NULL
AP3HR1	NULL
open	NULL
bar	NULL
in	NULL
B	NULL
)	NULL
.	NULL

EBNA2	NULL
and	NULL
EBNA2	NULL
mutants	NULL
can	NULL
be	NULL
transcribed	NULL
from	NULL
two	NULL
alternative	NULL
promoters	NULL
situated	NULL
in	NULL
the	NULL
C	NULL
or	NULL
W	NULL
fragments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
EBV	NULL
map	NULL
shows	NULL
in	NULL
addition	NULL
the	NULL
position	NULL
of	NULL
EBNAs	NULL
and	NULL
LMPs	NULL
transcribed	NULL
in	NULL
growth	NULL
transformed	NULL
B-cells	NULL
and	NULL
the	NULL
location	NULL
of	NULL
their	NULL
promoters	NULL
relative	NULL
to	NULL
the	NULL
BamHI	NULL
restriction	NULL
map	NULL
of	NULL
EBV	NULL
strain	NULL
B95.8	NULL
.	NULL

Table	NULL
I	NULL
.	NULL

Frequency	NULL
of	NULL
outgrowth	NULL
of	NULL
LCL	NULL
s	NULL
after	NULL
infection	NULL
with	NULL
viral	NULL
supernatants	NULL
Exp	NULL
.	NULL

Donor	NULL
p509	NULL
p554	NULL
+	NULL
p509	NULL
p554-3	NULL
+	NULL
p509	NULL
p554-4	NULL
+	NULL
p509	NULL
B	NULL
cell	NULL
source	NULL
Cells	NULL
plated	NULL
per	NULL
microwell	NULL
I	NULL
1	NULL
nd	NULL
.	NULL

32/48	NULL
nd	NULL
.	NULL

66196	NULL
CBL	NULL
80	NULL
000	NULL
II	NULL
2	NULL
8/48	NULL
9/48	NULL
nd	NULL
.	NULL

14/96	NULL
PBL	NULL
50	NULL
000	NULL
HI	NULL
3	NULL
0/48	NULL
29/48	NULL
nd	NULL
.	NULL

15796	NULL
CBL	NULL
100	NULL
000	NULL
VI	NULL
4	NULL
0/48	NULL
31/37	NULL
3/96	NULL
nd	NULL
.	NULL

CBL	NULL
75	NULL
000	NULL
v	NULL
5	NULL
0/48	NULL
48/48	NULL
6/96	NULL
14/96	NULL
CBL	NULL
100	NULL
000	NULL
v	NULL
6	NULL
nd	NULL
.	NULL

48/48	NULL
nd	NULL
.	NULL

nd	NULL
.	NULL

CBL	NULL
100	NULL
000	NULL
v	NULL
7	NULL
nd	NULL
.	NULL

48/48	NULL
5/48	NULL
18/96	NULL
CBL	NULL
100	NULL
000	NULL
v	NULL
8	NULL
nd	NULL
.	NULL

48/48	NULL
nd	NULL
.	NULL

22796	NULL
CBL	NULL
100	NULL
000	NULL
PBL	NULL
enriched	NULL
for	NULL
the	NULL
CD19	NULL
positive	NULL
B-cell	NULL
subpopulation	NULL
or	NULL
mononuclear	NULL
CBL	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
supernatants	NULL
of	NULL
HHS514	NULL
cells	NULL
which	NULL
had	NULL
been	NULL
transfected	NULL
with	NULL
:	NULL
p509	NULL
,	NULL
the	NULL
BZLF1	NULL
expression	NULL
plasmid	NULL
,	NULL
alone	NULL
or	NULL
co-transfected	NULL
with	NULL
p509	NULL
+	NULL
p554	NULL
,	NULL
the	NULL
wild-type	NULL
EBNA2	NULL
expression	NULL
mini-EBV	NULL
plasmid	NULL
,	NULL
or	NULL
p509	NULL
+	NULL
p554-3	NULL
or	NULL
p509	NULL
+	NULL
p554-4	NULL
,	NULL
the	NULL
EBNA2/ER	NULL
and	NULL
ER/EBNA2	NULL
expression	NULL
mini-EBV	NULL
plasmids	NULL
,	NULL
respectively	NULL
.	NULL

50-100	NULL
000	NULL
cells/well	NULL
were	NULL
seeded	NULL
into	NULL
96	NULL
well	NULL
culture	NULL
plates	NULL
on	NULL
irradiated	NULL
fibroblast	NULL
feeder	NULL
layers	NULL
.	NULL

In	NULL
five	NULL
experiments	NULL
using	NULL
independently	NULL
generated	NULL
viral	NULL
supernatants	NULL
specimens	NULL
from	NULL
eight	NULL
different	NULL
donors	NULL
were	NULL
studied	NULL
.	NULL

The	NULL
numbers	NULL
represent	NULL
numbers	NULL
of	NULL
growing	NULL
cultures	NULL
per	NULL
number	NULL
of	NULL
seeded	NULL
cultures	NULL
.	NULL

n.d.	NULL
:	NULL
not	NULL
done	NULL
.	NULL

CBL	NULL
:	NULL
cord	NULL
blood	NULL
lymphocytes	NULL
which	NULL
are	NULL
EBV	NULL
negative	NULL
.	NULL

PBL	NULL
:	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
of	NULL
seropositive	NULL
donors	NULL
which	NULL
gave	NULL
rise	NULL
to	NULL
hormone	NULL
dependent	NULL
as	NULL
well	NULL
as	NULL
spontaneously	NULL
outgrowing	NULL
LCLs	NULL
.	NULL

regulation	NULL
of	NULL
its	NULL
own	NULL
promoter	NULL
(	NULL
Sung	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Rooney	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

LMP1	NULL
belongs	NULL
to	NULL
the	NULL
group	NULL
of	NULL
viral	NULL
genes	NULL
known	NULL
to	NULL
be	NULL
transcriptionally	NULL
activated	NULL
by	NULL
EBNA2Z	NULL
.	NULL

It	NULL
is	NULL
the	NULL
only	NULL
EBV	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
.	NULL

Upon	NULL
removal	NULL
of	NULL
estrogen	NULL
,	NULL
LMP1	NULL
protein	NULL
was	NULL
significantly	NULL
down-regulated	NULL
,	NULL
indicating	NULL
that	NULL
LMP1	NULL
is	NULL
under	NULL
the	NULL
stringent	NULL
control	NULL
of	NULL
EBNA2	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

EBNA1	NULL
protein	NULL
,	NULL
in	NULL
contrast	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
latent	NULL
gene	NULL
defined	NULL
as	NULL
oncogenic	NULL
by	NULL
its	NULL
potential	NULL
to	NULL
transform	NULL
established	NULL
rodent	NULL
fibroblasts	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
enhances	NULL
the	NULL
expression	NULL
of	NULL
B-cell	NULL
activation	NULL
markers	NULL
and	NULL
induces	NULL
DNA	NULL
synthesis	NULL
in	NULL
resting	NULL
B-cells	NULL
(	NULL
Peng	NULL
and	NULL
Lundgren	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

LMP	NULL
!	NULL

1	NULL
was	NULL
expressed	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
conditional	NULL
mutant	NULL
virus	NULL
than	NULL
in	NULL
cells	NULL
transformed	NULL
by	NULL
wild-type	NULL
EBV	NULL
.	NULL

The	NULL
lower	NULL
level	NULL
of	NULL
LMP1	NULL
expression	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
slower	NULL
proliferation	NULL
of	NULL
cells	NULL
expressing	NULL
EBNA2/	NULL
estrogen	NULL
receptor	NULL
fusion	NULL
proteins	NULL
compared	NULL
with	NULL
cells	NULL
90	NULL
by	NULL
removal	NULL
of	NULL
estrogen	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
under	NULL
the	NULL
experimental	NULL
conditions	NULL
described	NULL
either	NULL
EBNA	NULL
1	NULL
is	NULL
very	NULL
stable	NULL
or	NULL
expression	NULL
of	NULL
EBNA1	NULL
does	NULL
not	NULL
require	NULL
EBNA2	NULL
.	NULL

Cells	NULL
are	NULL
arrested	NULL
in	NULL
G	NULL
;	NULL
and	NULL
G	NULL
;	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
upon	NULL
removal	NULL
of	NULL
estrogen	NULL
In	NULL
order	NULL
to	NULL
define	NULL
the	NULL
cell	NULL
cycle	NULL
status	NULL
of	NULL
growth	NULL
arrested	NULL
B-cells	NULL
we	NULL
determined	NULL
the	NULL
cellular	NULL
DNA	NULL
content	NULL
by	NULL
fluorescence	NULL
activated	NULL
cell	NULL
sorting	NULL
(	NULL
FACS	NULL
)	NULL
after	NULL
estrogen	NULL
A	NULL
08	NULL
]	NULL
fmm	NULL
me	NULL
-	NULL
no	NULL
estrogen	NULL
|	NULL
_	NULL
plus	NULL
estrogen	NULL
_	NULL
|	NULL
=	NULL
$	NULL
0	NULL
~a	NULL
m	NULL
ER/EBNA2	NULL
EBNA2/ER	NULL
EBNA2	NULL
ER/EBNA2	NULL
EBNAZ/ER	NULL
EBNA2	NULL
day	NULL
0	NULL
day	NULL
5	NULL
B	NULL
me	NULL
-	NULL
no	NULL
estrogen	NULL
as	NULL
-	NULL
plus	NULL
estrogen	NULL
3-H	NULL
thymidine	NULL
incorporation	NULL
(	NULL
x	NULL
1000	NULL
cpm	NULL
)	NULL
day	NULL
0	NULL
day	NULL
1	NULL
day	NULL
2	NULL
day	NULL
5	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Removal	NULL
of	NULL
estrogen	NULL
from	NULL
EBNAZ/estrogen	NULL
receptor-transformed	NULL
B-cells	NULL
results	NULL
in	NULL
growth	NULL
arrest	NULL
and	NULL
gradual	NULL
decrease	NULL
of	NULL
DNA	NULL
synthesis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Clones	NULL
expressing	NULL
either	NULL
ER/EBNA2	NULL
(	NULL
clone	NULL
ER/	NULL
EB2-5	NULL
)	NULL
,	NULL
EBNAZ/ER	NULL
(	NULL
clone	NULL
EB2/ER34	NULL
)	NULL
or	NULL
wild-type	NULL
EBNA2	NULL
(	NULL
clone	NULL
EB2-2	NULL
)	NULL
were	NULL
cultivated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
shaded	NULL
bars	NULL
)	NULL
or	NULL
absence	NULL
of	NULL
estrogen	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
for	NULL
5	NULL
days	NULL
and	NULL
cell	NULL
proliferation	NULL
determined	NULL
by	NULL
MTT	NULL
conversion	NULL
for	NULL
30	NULL
000	NULL
cells	NULL
on	NULL
day	NULL
0	NULL
and	NULL
5	NULL
after	NULL
seeding	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
DNA	NULL
synthesis	NULL
in	NULL
ER/EBNA2-expressing	NULL
B-cells	NULL
after	NULL
removal	NULL
of	NULL
estrogen	NULL
from	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

For	NULL
determination	NULL
of	NULL
DNA	NULL
synthesis	NULL
30	NULL
000	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
100	NULL
pl	NULL
per	NULL
well	NULL
on	NULL
day	NULL
0	NULL
and	NULL
kept	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
shaded	NULL
bars	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
of	NULL
estrogen	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
.	NULL

0.5	NULL
uCi	NULL
[	NULL
*HJthymidine	NULL
was	NULL
added	NULL
per	NULL
well	NULL
for	NULL
3	NULL
h	NULL
and	NULL
incorporation	NULL
of	NULL
radioactivity	NULL
determined	NULL
in	NULL
harvested	NULL
cells	NULL
.	NULL

removal	NULL
.	NULL

Withdrawal	NULL
of	NULL
hormone	NULL
from	NULL
the	NULL
culture	NULL
medium	NULL
severely	NULL
decreased	NULL
the	NULL
proportion	NULL
of	NULL
S-phase	NULL
cells	NULL
in	NULL
the	NULL
population	NULL
of	NULL
viable	NULL
cells	NULL
whereas	NULL
the	NULL
relative	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
G	NULL
;	NULL
versus	NULL
G	NULL
;	NULL
,	NULL
was	NULL
not	NULL
significantly	NULL
altered	NULL
.	NULL

The	NULL
relative	NULL
proportions	NULL
were	NULL
56	NULL
%	NULL
G	NULL
,	NULL
to	NULL
30	NULL
%	NULL
G	NULL
,	NULL
/M	NULL
cells	NULL
in	NULL
proliferating	NULL
cultures	NULL
,	NULL
and	NULL
68	NULL
%	NULL
G	NULL
,	NULL
to	NULL
30	NULL
%	NULL
G	NULL
,	NULL
/M	NULL
cells	NULL
in	NULL
growth	NULL
arrested	NULL
cultures	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
two	NULL
subpopulations	NULL
corresponding	NULL
to	NULL
G	NULL
;	NULL
-	NULL
and	NULL
G	NULL
,	NULL
-phase	NULL
cells	NULL
was	NULL
confirmed	NULL
by	NULL
fluorescence	NULL
in	NULL
situ	NULL
hybridization	NULL
using	NULL
a	NULL
biotin-labelled	NULL
immunoglobulin	NULL
A	NULL
gene	NULL
and	NULL
a	NULL
digoxigenin	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
centromere	NULL
of	NULL
chromosome	NULL
17	NULL
(	NULL
Lichter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Selig	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Since	NULL
centromeres	NULL
segregate	NULL
only	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
mitosis	NULL
,	NULL
the	NULL
centromere-specific	NULL
hybridization	NULL
signals	NULL
serve	NULL
as	NULL
control	NULL
for	NULL
the	NULL
diploidy	NULL
of	NULL
the	NULL
cell	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

No	NULL
metaphase	NULL
chromosomes	NULL
were	NULL
detected	NULL
in	NULL
growth	NULL
arrested	NULL
cell	NULL
populations	NULL
indicating	NULL
that	NULL
progression	NULL
into	NULL
mitosis	NULL
was	NULL
inhibited	NULL
.	NULL

Since	NULL
the	NULL
distribution	NULL
of	NULL
cells	NULL
in	NULL
G	NULL
;	NULL
and	NULL
G	NULL
,	NULL
was	NULL
not	NULL
altered	NULL
significantly	NULL
after	NULL
estrogen	NULL
depletion	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
G	NULL
;	NULL
and	NULL
G	NULL
,	NULL
cells	NULL
indicates	NULL
that	NULL
at	NULL
least	NULL
two	NULL
restriction	NULL
points	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
before	NULL
and	NULL
after	NULL
the	NULL
S	NULL
phase	NULL
,	NULL
are	NULL
directly	NULL
or	NULL
indirectly	NULL
controlled	NULL
by	NULL
EBNA2	NULL
.	NULL

EBV	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-regulating	NULL
proteins	NULL
m	NULL
a	NULL
o	NULL
o	NULL
wo	NULL
a	NULL
oa	NULL
~	NULL
a	NULL
«	NULL
v	NULL
y	NULL
A	NULL
a	NULL
a	NULL
a	NULL
E	NULL
i	NULL
»	NULL
-W	NULL
w	NULL
Ww	NULL
W	NULL
8	NULL
8	NULL
c	NULL
c	NULL
ac	NULL
E	NULL
&	NULL
wo	NULL
w	NULL
uw	NULL
u	NULL
;	NULL
uj	NULL
uj	NULL
o	NULL
}	NULL
6	NULL
$	NULL
00	NULL
-	NULL
0	NULL
$	NULL
00	NULL
-	NULL
#	NULL
00	NULL
-	NULL
o-	NULL
estrogen	NULL
116	NULL
~	NULL
@	NULL
A	NULL
...	NULL
B	NULL
am	NULL
<	NULL
4	NULL
ER/EBNA2	NULL
s	NULL
_	NULL
.	NULL

®t	NULL
me	NULL
4	NULL
EBNA2	NULL
so	NULL
-	NULL
»	NULL
-	NULL
aa	NULL
»	NULL
@	NULL
<	NULL
wP	NULL
P	NULL
<	NULL
ccNnl	NULL
so	NULL
_-	NULL
@	NULL
Gt	NULL
~~	NULL
«	NULL
-	NULL
<	NULL
4	NULL
-	NULL
LMP1	NULL
49	NULL
_	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

LMPI	NULL
is	NULL
down-regulated	NULL
in	NULL
ER/EBNA2-expressing	NULL
clones	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
estrogen	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
after	NULL
cultivation	NULL
for	NULL
3	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
estrogen	NULL
,	NULL
lysed	NULL
and	NULL
the	NULL
extracts	NULL
analysed	NULL
by	NULL
Western	NULL
blotting	NULL
for	NULL
EBNAZ	NULL
,	NULL
EBNA	NULL
!	NULL

1	NULL
and	NULL
LMP1	NULL
expression	NULL
.	NULL

Cells	NULL
arrested	NULL
in	NULL
G	NULL
;	NULL
phase	NULL
re-enter	NULL
the	NULL
cell	NULL
cycle	NULL
upon	NULL
addition	NULL
of	NULL
estrogen	NULL
DNA	NULL
synthesis	NULL
could	NULL
be	NULL
re-induced	NULL
in	NULL
the	NULL
non-apoptotic	NULL
subpopulation	NULL
~18	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
estrogen	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

Cytogenetic	NULL
analyses	NULL
of	NULL
the	NULL
cells	NULL
released	NULL
from	NULL
growth	NULL
arrest	NULL
revealed	NULL
that	NULL
cells	NULL
in	NULL
metaphase	NULL
of	NULL
mitosis	NULL
were	NULL
only	NULL
detected	NULL
after	NULL
the	NULL
onset	NULL
of	NULL
DNA	NULL
synthesis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
no	NULL
metaphase	NULL
plates	NULL
were	NULL
detected	NULL
when	NULL
DNA	NULL
synthesis	NULL
was	NULL
inhibited	NULL
by	NULL
metothrexate	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
only	NULL
cells	NULL
arrested	NULL
in	NULL
G	NULL
;	NULL
are	NULL
capable	NULL
of	NULL
re-entering	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

To	NULL
address	NULL
the	NULL
mechanism	NULL
of	NULL
EBNA2-dependent	NULL
growth	NULL
control	NULL
in	NULL
our	NULL
experimental	NULL
system	NULL
,	NULL
we	NULL
analysed	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
cellular	NULL
and	NULL
viral	NULL
proteins	NULL
which	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
DNA	NULL
synthesis	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

LMP1	NULL
and	NULL
MYC	NULL
expression	NULL
was	NULL
induced	NULL
as	NULL
early	NULL
as	NULL
3	NULL
h	NULL
after	NULL
estrogen	NULL
addition	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

Both	NULL
genes	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
induce	NULL
DNA	NULL
synthesis	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
Eilers	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Peng	NULL
and	NULL
Lundgren	NULL
,	NULL
1992	NULL
)	NULL
and	NULL
could	NULL
play	NULL
a	NULL
key	NULL
role	NULL
in	NULL
initiating	NULL
the	NULL
re-entry	NULL
of	NULL
the	NULL
cells	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Cyclins	NULL
are	NULL
regulatory	NULL
subunits	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
(	NULL
ecdks	NULL
or	NULL
edes	NULL
)	NULL
,	NULL
which	NULL
regulate	NULL
progression	NULL
of	NULL
cells	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

The	NULL
cyclin	NULL
partners	NULL
of	NULL
cdk4	NULL
are	NULL
of	NULL
D-type	NULL
,	NULL
edk2	NULL
associates	NULL
preferentially	NULL
with	NULL
cyclin	NULL
E	NULL
and	NULL
cyclin	NULL
A	NULL
,	NULL
cdc2	NULL
forms	NULL
complexes	NULL
with	NULL
cyclins	NULL
A	NULL
and	NULL
B	NULL
which	NULL
are	NULL
functional	NULL
in	NULL
G	NULL
,	NULL
(	NULL
reviewed	NULL
in	NULL
Sherr	NULL
,	NULL
1993	NULL
;	NULL
Pines	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
D	NULL
cyclins	NULL
,	NULL
which	NULL
are	NULL
expressed	NULL
early	NULL
in	NULL
G1	NULL
in	NULL
mammalian	NULL
cells	NULL
,	NULL
cyclin	NULL
D2	NULL
became	NULL
detectable	NULL
after	NULL
5-7	NULL
h	NULL
followed	NULL
by	NULL
Cdk4	NULL
~2	NULL
h	NULL
later	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

Neither	NULL
cyclin	NULL
D1	NULL
nor	NULL
cyclin	NULL
D3	NULL
could	NULL
be	NULL
detected	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
cyclin	NULL
D2	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
EBV-transformed	NULL
cells	NULL
(	NULL
Palmero	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Cyclin	NULL
D2	NULL
up-regulation	NULL
preceded	NULL
the	NULL
modification	NULL
of	NULL
Rb	NULL
observed	NULL
10	NULL
h	NULL
after	NULL
addition	NULL
of	NULL
hormone	NULL
,	NULL
when	NULL
part	NULL
of	NULL
the	NULL
Rb	NULL
protein	NULL
started	NULL
to	NULL
migrate	NULL
more	NULL
slowly	NULL
presumably	NULL
representing	NULL
a	NULL
phosphorylated	NULL
form	NULL
of	NULL
Rb	NULL
.	NULL

E2F1	NULL
,	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
genes	NULL
involved	NULL
in	NULL
DNA	NULL
synthesis	NULL
91	NULL
B.Kempkes	NULL
et	NULL
al	NULL
.	NULL

+	NULL
estrogen	NULL
14UI	NULL
‘	NULL
i	NULL
120	NULL
}	NULL
cell	NULL
number	NULL
DNA	NULL
content	NULL
-	NULL
estrogen	NULL
160	NULL
)	NULL
+	NULL
+	NULL
--	NULL
-+	NULL
+	NULL
T	NULL
>	NULL
|	NULL
1	NULL
i	NULL
N	NULL
|	NULL
DNA	NULL
content	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cell	NULL
cycle	NULL
status	NULL
in	NULL
proliferating	NULL
and	NULL
non-proliferating	NULL
estrogen-deprived	NULL
cultures	NULL
.	NULL

ER/EBNAZ-expressing	NULL
transformed	NULL
B-cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
estrogen	NULL
for	NULL
4	NULL
days	NULL
.	NULL

The	NULL
DNA	NULL
content	NULL
was	NULL
determined	NULL
after	NULL
staining	NULL
with	NULL
Hoechst	NULL
33342	NULL
and	NULL
propidium	NULL
iodide	NULL
.	NULL

Apoptotic	NULL
and	NULL
dead	NULL
cells	NULL
were	NULL
excluded	NULL
from	NULL
the	NULL
analysis	NULL
,	NULL
since	NULL
their	NULL
degraded	NULL
DNA	NULL
overlapped	NULL
the	NULL
S-phase	NULL
signals	NULL
and	NULL
obscured	NULL
the	NULL
results	NULL
.	NULL

The	NULL
dots	NULL
represent	NULL
the	NULL
direct	NULL
results	NULL
of	NULL
the	NULL
measurements	NULL
.	NULL

The	NULL
lines	NULL
indicate	NULL
the	NULL
relative	NULL
calculated	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
G	NULL
;	NULL
(	NULL
punctuated	NULL
)	NULL
,	NULL
S	NULL
(	NULL
diagonally	NULL
hatched	NULL
)	NULL
and	NULL
G	NULL
;	NULL
(	NULL
vertically	NULL
hatched	NULL
area	NULL
)	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

which	NULL
is	NULL
maintained	NULL
inactive	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
hypophos-phorylated	NULL
form	NULL
of	NULL
Rb	NULL
(	NULL
Helin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
became	NULL
detectable	NULL
concomitantly	NULL
with	NULL
the	NULL
modification	NULL
of	NULL
Rb	NULL
.	NULL

Cyclin	NULL
E	NULL
was	NULL
constitutively	NULL
expressed	NULL
at	NULL
low	NULL
level	NULL
and	NULL
increased	NULL
significantly	NULL
12-16	NULL
h	NULL
after	NULL
estrogen	NULL
addition	NULL
.	NULL

Remarkably	NULL
,	NULL
despite	NULL
a	NULL
significant	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
(	NULL
30	NULL
%	NULL
)	NULL
,	NULL
cyclin	NULL
A	NULL
and	NULL
cyclin	NULL
B1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
absent	NULL
from	NULL
estrogen-deprived	NULL
cells	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
hormone	NULL
,	NULL
cyclin	NULL
A	NULL
was	NULL
first	NULL
detected	NULL
before	NULL
cells	NULL
entered	NULL
the	NULL
S	NULL
phase	NULL
.	NULL

Since	NULL
cyclin	NULL
A	NULL
and	NULL
cyclin	NULL
B	NULL
are	NULL
required	NULL
for	NULL
G	NULL
;	NULL
,	NULL
/M	NULL
transition	NULL
(	NULL
Pagano	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
the	NULL
absence	NULL
of	NULL
both	NULL
cyclins	NULL
may	NULL
explain	NULL
the	NULL
failure	NULL
of	NULL
cells	NULL
at	NULL
the	NULL
G	NULL
;	NULL
stage	NULL
to	NULL
enter	NULL
mitosis	NULL
upon	NULL
addition	NULL
of	NULL
estrogen	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
p53	NULL
,	NULL
cdc2	NULL
and	NULL
cdk2	NULL
,	NULL
which	NULL
are	NULL
expressed	NULL
in	NULL
growth	NULL
arrested	NULL
ER/EBNA2Z	NULL
cells	NULL
,	NULL
stayed	NULL
fairly	NULL
constant	NULL
or	NULL
increased	NULL
gradually	NULL
throughout	NULL
the	NULL
experiment	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Figure	NULL
6B	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
,	NULL
expression	NULL
of	NULL
all	NULL
proteins	NULL
analysed	NULL
during	NULL
our	NULL
studies	NULL
was	NULL
unaffected	NULL
by	NULL
estrogen	NULL
in	NULL
EBV-transformed	NULL
cell	NULL
clones	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
(	NULL
EB2-3	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
cyclin	NULL
and	NULL
cyclin-dependent	NULL
kinase	NULL
gene	NULL
expression	NULL
was	NULL
identical	NULL
in	NULL
primary	NULL
B-cells	NULL
infected	NULL
by	NULL
EBV	NULL
in	NULL
vitro	NULL
and	NULL
the	NULL
conditionally	NULL
transformed	NULL
lymphoblastoid	NULL
cells	NULL
restimulated	NULL
with	NULL
estrogen	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

EBV	NULL
and	NULL
polyclonal	NULL
B	NULL
cell	NULL
stimuli	NULL
activate	NULL
a	NULL
common	NULL
pathway	NULL
for	NULL
cell	NULL
cycle	NULL
entry	NULL
The	NULL
expression	NULL
pattern	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
genes	NULL
accumulating	NULL
at	NULL
specific	NULL
stages	NULL
before	NULL
and	NULL
during	NULL
the	NULL
onset	NULL
of	NULL
S	NULL
phase	NULL
indicated	NULL
that	NULL
the	NULL
estrogen-deprived	NULL
cells	NULL
which	NULL
re-entered	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
upon	NULL
addition	NULL
of	NULL
estrogen	NULL
had	NULL
been	NULL
arrested	NULL
in	NULL
early	NULL
G	NULL
,	NULL
phase	NULL
.	NULL

Induction	NULL
of	NULL
proliferation	NULL
of	NULL
normal	NULL
resting	NULL
B-cells	NULL
can	NULL
be	NULL
achieved	NULL
by	NULL
CD40	NULL
92	NULL
ligand	NULL
or	NULL
anti-CD40	NULL
antibodies	NULL
mimicking	NULL
T-cell-dependent	NULL
B-cell	NULL
activation	NULL
(	NULL
Banchereau	NULL
,	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
or	NULL
by	NULL
Staphylococcus	NULL
aureus	NULL
particles	NULL
mimicking	NULL
antigen	NULL
binding	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
EBV	NULL
is	NULL
using	NULL
the	NULL
same	NULL
or	NULL
a	NULL
different	NULL
pathway	NULL
for	NULL
induction	NULL
of	NULL
proliferation	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
pattern	NULL
of	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
genes	NULL
observed	NULL
after	NULL
anti-CD40	NULL
and	NULL
SAC	NULL
treatment	NULL
with	NULL
that	NULL
induced	NULL
by	NULL
EBV	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
7	NULL
,	NULL
cyclins	NULL
D2	NULL
,	NULL
E	NULL
and	NULL
cdk4	NULL
were	NULL
absent	NULL
from	NULL
resting	NULL
cells	NULL
and	NULL
were	NULL
induced	NULL
by	NULL
anti-CD40	NULL
antibodies	NULL
and	NULL
S.auwreus	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cdk2	NULL
was	NULL
already	NULL
present	NULL
in	NULL
resting	NULL
cells	NULL
and	NULL
expression	NULL
did	NULL
not	NULL
change	NULL
significantly	NULL
following	NULL
either	NULL
treatment	NULL
.	NULL

CD40	NULL
and	NULL
S.aureus	NULL
thus	NULL
induce	NULL
the	NULL
same	NULL
set	NULL
of	NULL
proteins	NULL
as	NULL
infection	NULL
of	NULL
cell	NULL
with	NULL
EBV	NULL
or	NULL
reactivation	NULL
of	NULL
EBNA2	NULL
in	NULL
our	NULL
model	NULL
system	NULL
.	NULL

We	NULL
may	NULL
conclude	NULL
that	NULL
stimulation	NULL
of	NULL
growth	NULL
by	NULL
EBV	NULL
is	NULL
induced	NULL
through	NULL
a	NULL
pathway	NULL
which	NULL
is	NULL
also	NULL
physiologically	NULL
used	NULL
for	NULL
polyclonal	NULL
B-cell	NULL
activation	NULL
.	NULL

Discussion	NULL
Studies	NULL
aiming	NULL
to	NULL
elucidate	NULL
the	NULL
growth	NULL
promoting	NULL
potential	NULL
of	NULL
EBV	NULL
genes	NULL
by	NULL
introducing	NULL
them	NULL
into	NULL
B-cells	NULL
face	NULL
a	NULL
general	NULL
problem	NULL
.	NULL

Expression	NULL
of	NULL
viral	NULL
genes	NULL
in	NULL
continuously	NULL
proliferating	NULL
B-cell	NULL
lymphoma	NULL
lines	NULL
is	NULL
feasible	NULL
and	NULL
also	NULL
potentially	NULL
useful	NULL
for	NULL
biochemical	NULL
characterization	NULL
of	NULL
the	NULL
viral	NULL
gene	NULL
product	NULL
.	NULL

However	NULL
,	NULL
since	NULL
the	NULL
cells	NULL
are	NULL
already	NULL
continuously	NULL
proliferating	NULL
for	NULL
reasons	NULL
unrelated	NULL
to	NULL
EBV	NULL
infection	NULL
,	NULL
this	NULL
approach	NULL
by	NULL
definition	NULL
precludes	NULL
an	NULL
answer	NULL
to	NULL
the	NULL
question	NULL
of	NULL
what	NULL
the	NULL
viral	NULL
gene	NULL
product	NULL
might	NULL
contribute	NULL
to	NULL
growth	NULL
regulation	NULL
.	NULL

To	NULL
study	NULL
growth	NULL
control	NULL
,	NULL
primary	NULL
resting	NULL
B-cells	NULL
are	NULL
the	NULL
only	NULL
relevant	NULL
target	NULL
.	NULL

However	NULL
,	NULL
no	NULL
one	NULL
has	NULL
ever	NULL
succeeded	NULL
in	NULL
transforming	NULL
of	NULL
primary	NULL
G1	NULL
-	NULL
phase	NULL
cells	NULL
+	NULL
estrogen	NULL
-	NULL
estrogen	NULL
EBV	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-regulating	NULL
proteins	NULL
62	NULL
-	NULL
phase	NULL
cells	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Cell	NULL
cycle	NULL
analysis	NULL
by	NULL
in	NULL
situ	NULL
hybridization	NULL
of	NULL
interphase	NULL
nuclei	NULL
.	NULL

R/EBNA2-5	NULL
nuclei	NULL
of	NULL
cultures	NULL
grown	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
a	NULL
and	NULL
b	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
e	NULL
and	NULL
d	NULL
)	NULL
of	NULL
estrogen	NULL
were	NULL
hybridized	NULL
simultaneously	NULL
with	NULL
a	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
Igl	NULL
locus	NULL
(	NULL
Combriato	NULL
and	NULL
Klobeck	NULL
,	NULL
1991	NULL
,	NULL
green	NULL
fluorescence	NULL
)	NULL
and	NULL
a	NULL
second	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
centromere	NULL
of	NULL
chromosome	NULL
17	NULL
(	NULL
Selig	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
,	NULL
red	NULL
fluorescence	NULL
)	NULL
.	NULL

Following	NULL
in	NULL
situ	NULL
hybridization	NULL
,	NULL
unreplicated	NULL
gene	NULL
loci	NULL
in	NULL
interphase	NULL
nuclei	NULL
give	NULL
rise	NULL
to	NULL
singlet	NULL
and	NULL
replicated	NULL
DNA	NULL
loci	NULL
to	NULL
doublet	NULL
signals	NULL
.	NULL

Centromere-specific	NULL
probes	NULL
appear	NULL
as	NULL
bright	NULL
singlet	NULL
signals	NULL
in	NULL
interphase	NULL
nuclei	NULL
and	NULL
can	NULL
serve	NULL
as	NULL
internal	NULL
control	NULL
for	NULL
the	NULL
ploidy	NULL
of	NULL
the	NULL
cell	NULL
.	NULL

The	NULL
intactness	NULL
of	NULL
the	NULL
nuclei	NULL
was	NULL
monitored	NULL
by	NULL
morphology	NULL
after	NULL
diamidinophenylindole	NULL
(	NULL
DAPI	NULL
)	NULL
staining	NULL
.	NULL

Nuclei	NULL
containing	NULL
singlet	NULL
and	NULL
doublet	NULL
signals	NULL
were	NULL
present	NULL
in	NULL
estrogen	NULL
containing	NULL
as	NULL
well	NULL
as	NULL
estrogen-deprived	NULL
ER/EBNA2-5	NULL
cells	NULL
indicating	NULL
that	NULL
estrogen-deprived	NULL
cells	NULL
were	NULL
arrested	NULL
in	NULL
G	NULL
;	NULL
as	NULL
well	NULL
as	NULL
G	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

resting	NULL
B-cells	NULL
into	NULL
continuously	NULL
proliferating	NULL
cell	NULL
lines	NULL
by	NULL
transfection	NULL
of	NULL
intact	NULL
viral	NULL
DNA	NULL
or	NULL
DNA	NULL
fragments	NULL
.	NULL

It	NULL
remains	NULL
an	NULL
open	NULL
question	NULL
whether	NULL
all	NULL
failures	NULL
to	NULL
transform	NULL
B-cells	NULL
by	NULL
transfection	NULL
of	NULL
EBV	NULL
DNA	NULL
have	NULL
been	NULL
due	NULL
to	NULL
the	NULL
inefficiency	NULL
of	NULL
DNA	NULL
transfer	NULL
into	NULL
primary	NULL
B-cells	NULL
or	NULL
whether	NULL
infection	NULL
of	NULL
resting	NULL
cells	NULL
by	NULL
virus	NULL
particles	NULL
is	NULL
a	NULL
crucial	NULL
event	NULL
in	NULL
the	NULL
transformation	NULL
process	NULL
.	NULL

Our	NULL
experimental	NULL
system	NULL
of	NULL
primary	NULL
B-cells	NULL
,	NULL
which	NULL
are	NULL
conditionally	NULL
transformed	NULL
by	NULL
recombinant	NULL
virus	NULL
,	NULL
provides	NULL
a	NULL
way	NULL
out	NULL
of	NULL
this	NULL
dilemma	NULL
and	NULL
allows	NULL
,	NULL
for	NULL
the	NULL
first	NULL
time	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
function	NULL
of	NULL
a	NULL
viral	NULL
gene	NULL
product	NULL
on	NULL
the	NULL
genetic	NULL
background	NULL
of	NULL
a	NULL
normal	NULL
B-cell	NULL
transformed	NULL
by	NULL
EBV	NULL
in	NULL
vitro	NULL
.	NULL

Studying	NULL
the	NULL
role	NULL
of	NULL
a	NULL
conditional	NULL
EBNA2	NULL
protein	NULL
in	NULL
B-cell	NULL
proliferation	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
demonstrate	NULL
that	NULL
EBNA2Z	NULL
not	NULL
only	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
cascade	NULL
of	NULL
events	NULL
leading	NULL
to	NULL
B-cell	NULL
transformation	NULL
but	NULL
is	NULL
also	NULL
essential	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
the	NULL
transformed	NULL
state	NULL
.	NULL

Cells	NULL
deprived	NULL
of	NULL
functional	NULL
EBNA2	NULL
enter	NULL
a	NULL
quiescent	NULL
non-proliferating	NULL
state	NULL
reminiscent	NULL
of	NULL
normal	NULL
resting	NULL
B-cells	NULL
or	NULL
die	NULL
by	NULL
apoptosis	NULL
.	NULL

Growth	NULL
arrest	NULL
occurs	NULL
at	NULL
more	NULL
than	NULL
one	NULL
point	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Functional	NULL
EBNA2Z	NULL
is	NULL
thus	NULL
required	NULL
in	NULL
G	NULL
,	NULL
;	NULL
and	NULL
G	NULL
;	NULL
,	NULL
and	NULL
a	NULL
role	NULL
in	NULL
terminating	NULL
S	NULL
phase	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

Re-induction	NULL
of	NULL
growth	NULL
is	NULL
possible	NULL
,	NULL
but	NULL
confined	NULL
to	NULL
a	NULL
subpopulation	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-phase	NULL
cells	NULL
.	NULL

Removal	NULL
of	NULL
functional	NULL
EBNA2	NULL
is	NULL
accompanied	NULL
by	NULL
a	NULL
shut-off	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
genes	NULL
involved	NULL
in	NULL
proliferation	NULL
such	NULL
as	NULL
myc	NULL
and	NULL
LMP	NULL
]	NULL
.	NULL

Whether	NULL
the	NULL
c-myc	NULL
gene	NULL
is	NULL
a	NULL
direct	NULL
or	NULL
indirect	NULL
target	NULL
of	NULL
EBNA2	NULL
,	NULL
remains	NULL
to	NULL
be	NULL
shown	NULL
.	NULL

Re-induction	NULL
of	NULL
growth	NULL
was	NULL
accompanied	NULL
by	NULL
sequential	NULL
accumulation	NULL
and	NULL
modification	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
.	NULL

Expression	NULL
of	NULL
LMP1	NULL
and	NULL
MYC	NULL
preceded	NULL
accumulation	NULL
of	NULL
E2F-1	NULL
suggesting	NULL
that	NULL
E2F-1	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
c-myc	NULL
after	NULL
reactivation	NULL
of	NULL
EBNA2	NULL
.	NULL

Since	NULL
the	NULL
e-myc	NULL
gene	NULL
contains	NULL
an	NULL
93	NULL
B.Kempkes	NULL
et	NULL
al	NULL
.	NULL

50	NULL
40	NULL
|	NULL
5	NULL
30	NULL
|	NULL
G	NULL
|	NULL
fe	NULL
|	NULL
Cyclin	NULL
D2	NULL
3	NULL
20	NULL
|	NULL
|	NULL
p	NULL
g	NULL
=-	NULL
10	NULL
|	NULL
Cyclin	NULL
E	NULL
I	NULL
~	NULL
0	NULL
3	NULL
5	NULL
7	NULL
8	NULL
10121618	NULL
202224	NULL
Cyclin	NULL
A	NULL
hours	NULL
following	NULL
addition	NULL
of	NULL
estroger	NULL
Rb	NULL
p53	NULL
LP	NULL
‘	NULL
APX	NULL
--	NULL
-	NULL
ama	NULL
aun	NULL
A00	NULL
aum	NULL
Aub	NULL
woh	NULL
men	NULL
-~	NULL
E2F-1	NULL
MYC	NULL
3	NULL
@	NULL
-	NULL
aa	NULL
0	NULL
«	NULL
*	NULL
&	NULL
a	NULL
a	NULL
a	NULL
«	NULL
#	NULL
cdk2	NULL
cdk4	NULL
cdc2	NULL
5	NULL
g	NULL
®	NULL
®	NULL
®	NULL
c	NULL
o	NULL
0	NULL
5	NULL
E	NULL
i	NULL
5	NULL
F	NULL
®	NULL
o	NULL
~	NULL
o	NULL
evar	NULL
iain	NULL
_	NULL
ou	NULL
ou	NULL
*	NULL
hours	NULL
following	NULL
estrogen	NULL
stimulation	NULL
m	NULL
M	NULL
e	NULL
o	NULL
.	NULL

W	NULL
W	NULL
cq	NULL
cu	NULL
J	NULL
s	NULL
»	NULL
4A	NULL
aRIBN	NULL
ao	NULL
5a	NULL
C	NULL
C	NULL
m	NULL
m	NULL
a	NULL
12	NULL
16	NULL
18	NULL
20	NULL
22	NULL
24	NULL
w	NULL
w	NULL
w	NULL
LW	NULL
co	NULL
&	NULL
-	NULL
wdbe	NULL
@	NULL
-	NULL
@	NULL
-	NULL
»	NULL
»	NULL
``	NULL
m	NULL
»	NULL
-	NULL
cnabas	NULL
«	NULL
mo	NULL
amp	NULL
cus	NULL
w	NULL
wut	NULL
#	NULL
@	NULL
*	NULL
bard	NULL
«	NULL
--	NULL
ae	NULL
,	NULL
gor	NULL
<	NULL
c-wm	NULL
‘	NULL
<	NULL
»	NULL
«	NULL
=-	NULL
«	NULL
tv	NULL
mes	NULL
<	NULL
n	NULL
titts	NULL
mace	NULL
coms	NULL
come	NULL
commom	NULL
«	NULL
s	NULL
«	NULL
s	NULL
ap	NULL
a6	NULL
``	NULL
P	NULL
<	NULL
a	NULL
>	NULL
<	NULL
P	NULL
Gp	NULL
<	NULL
»	NULL
*	NULL
@	NULL
wer	NULL
--	NULL
<	NULL
a	NULL
>	NULL
fp	NULL
«	NULL
--	NULL
«	NULL
»	NULL
ar	NULL
a	NULL
»	NULL
«	NULL
»	NULL
«	NULL
»	NULL
a	NULL
»	NULL
Gar	NULL
A	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Reversion	NULL
of	NULL
growth	NULL
arrest	NULL
by	NULL
estrogen	NULL
and	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
related	NULL
genes	NULL
after	NULL
release	NULL
from	NULL
growth	NULL
arrest	NULL
.	NULL

(	NULL
A	NULL
)	NULL
ER/EBNA2	NULL
expressing	NULL
cells	NULL
(	NULL
clone	NULL
ER/EB2-5	NULL
)	NULL
were	NULL
deprived	NULL
of	NULL
estrogen	NULL
for	NULL
4	NULL
days	NULL
until	NULL
DNA	NULL
synthesis	NULL
had	NULL
virtually	NULL
ceased	NULL
.	NULL

Estrogen	NULL
was	NULL
readded	NULL
to	NULL
the	NULL
cultures	NULL
and	NULL
parallel	NULL
cultures	NULL
were	NULL
tested	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
and	NULL
re-expression	NULL
of	NULL
LMP1	NULL
and	NULL
MYC	NULL
protein	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cultures	NULL
as	NULL
described	NULL
in	NULL
(	NULL
A	NULL
)	NULL
were	NULL
tested	NULL
for	NULL
expression	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
E	NULL
,	NULL
A	NULL
,	NULL
of	NULL
cdk4	NULL
,	NULL
cdk2	NULL
,	NULL
cdc2	NULL
and	NULL
of	NULL
p53	NULL
,	NULL
and	NULL
Rb	NULL
,	NULL
and	NULL
E2F1	NULL
protein	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
BPL2	NULL
,	NULL
a	NULL
second	NULL
ER/EBNA2	NULL
expressing	NULL
clone	NULL
(	NULL
ER/EB2-3	NULL
)	NULL
and	NULL
a	NULL
wild-type	NULL
EBNA2	NULL
expressing	NULL
clone	NULL
(	NULL
EB2-3	NULL
)	NULL
,	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
estrogen	NULL
,	NULL
were	NULL
analysed	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
same	NULL
set	NULL
of	NULL
proteins	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

E2F	NULL
site	NULL
in	NULL
front	NULL
of	NULL
the	NULL
second	NULL
promoter	NULL
(	NULL
Thalmeier	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Hiebert	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
see	NULL
whether	NULL
other	NULL
members	NULL
of	NULL
the	NULL
E2F	NULL
family	NULL
participate	NULL
in	NULL
the	NULL
EBNA2-induced	NULL
c-myc	NULL
activation	NULL
.	NULL

LMPI	NULL
and	NULL
MYC	NULL
expression	NULL
was	NULL
followed	NULL
by	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
,	NULL
regulating	NULL
proteins	NULL
,	NULL
like	NULL
cyclin	NULL
D2	NULL
and	NULL
cdk4	NULL
,	NULL
while	NULL
cdc2	NULL
and	NULL
cdk2	NULL
were	NULL
constitutively	NULL
expressed	NULL
.	NULL

Cdk4	NULL
is	NULL
induced	NULL
after	NULL
stimulation	NULL
of	NULL
serum-deprived	NULL
macrophages	NULL
with	NULL
CSF-1	NULL
and	NULL
addition	NULL
of	NULL
serum	NULL
to	NULL
serum-starved	NULL
fibroblasts	NULL
.	NULL

Cdk4	NULL
complexes	NULL
contribute	NULL
to	NULL
cyclin	NULL
Di-dependent	NULL
phos-phorylation	NULL
of	NULL
Rb	NULL
(	NULL
Matsushime	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
cyclins	NULL
D2	NULL
and	NULL
cdk4	NULL
was	NULL
not	NULL
only	NULL
observed	NULL
after	NULL
addition	NULL
of	NULL
estrogen	NULL
,	NULL
but	NULL
also	NULL
after	NULL
primary	NULL
infection	NULL
of	NULL
B-cells	NULL
with	NULL
EBV	NULL
.	NULL

Reactivation	NULL
of	NULL
EBNA2	NULL
in	NULL
conditionally	NULL
transformed	NULL
cells	NULL
is	NULL
thus	NULL
indeed	NULL
mimicking	NULL
the	NULL
early	NULL
events	NULL
in	NULL
the	NULL
process	NULL
of	NULL
B-cell	NULL
transformation	NULL
by	NULL
EBV	NULL
.	NULL

Adenovirus	NULL
EIA	NULL
was	NULL
recently	NULL
shown	NULL
to	NULL
perturb	NULL
the	NULL
cascade	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
genes	NULL
.	NULL

After	NULL
cotransforma-tion	NULL
of	NULL
rat	NULL
embryo	NULL
fibroblasts	NULL
with	NULL
an	NULL
activated	NULL
ras	NULL
gene	NULL
E1A	NULL
induces	NULL
cyclin	NULL
A	NULL
and	NULL
E	NULL
,	NULL
and	NULL
represses	NULL
cyclin	NULL
D1	NULL
expression	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
growth	NULL
factors	NULL
which	NULL
sequentially	NULL
activate	NULL
cyclins	NULL
D1	NULL
,	NULL
E	NULL
and	NULL
A	NULL
in	NULL
the	NULL
same	NULL
type	NULL
of	NULL
cells	NULL
94	NULL
(	NULL
Spitkovsky	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
is	NULL
now	NULL
apparent	NULL
that	NULL
different	NULL
D	NULL
cyclins	NULL
are	NULL
expressed	NULL
in	NULL
different	NULL
types	NULL
of	NULL
human	NULL
B-cell	NULL
tumours	NULL
.	NULL

Expression	NULL
of	NULL
cyclin	NULL
D1	NULL
is	NULL
a	NULL
hallmark	NULL
of	NULL
lymphomas	NULL
with	NULL
a	NULL
t	NULL
(	NULL
11	NULL
;	NULL
14	NULL
)	NULL
(	NULL
q13	NULL
;	NULL
q32	NULL
)	NULL
trans-location	NULL
affecting	NULL
the	NULL
BCL-1/PRAD-1	NULL
locus	NULL
(	NULL
Palmero	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Rimokh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Akiyama	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
whereas	NULL
EBV-negative	NULL
and	NULL
group	NULL
I	NULL
Burkitt	NULL
lymphoma	NULL
cells	NULL
express	NULL
cyclin	NULL
D3	NULL
(	NULL
Palmero	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

It	NULL
was	NULL
therefore	NULL
interesting	NULL
to	NULL
compare	NULL
the	NULL
pattern	NULL
of	NULL
cyclins	NULL
and	NULL
cyclin-dependent	NULL
kinases	NULL
induced	NULL
by	NULL
EBV	NULL
and	NULL
polyclonal	NULL
B-cell	NULL
stimuli	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
the	NULL
same	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
are	NULL
induced	NULL
by	NULL
EBV	NULL
,	NULL
CD40	NULL
,	NULL
and	NULL
S.aureus	NULL
suggests	NULL
that	NULL
EBV	NULL
mimics	NULL
continuously	NULL
ongoing	NULL
B-cell	NULL
activation	NULL
,	NULL
bypassing	NULL
the	NULL
requirement	NULL
for	NULL
stimulation	NULL
by	NULL
antigen	NULL
,	NULL
T-cell	NULL
signals	NULL
and/or	NULL
growth	NULL
factors	NULL
.	NULL

The	NULL
chronological	NULL
order	NULL
of	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
regulating	NULL
proteins	NULL
observed	NULL
after	NULL
reactivation	NULL
of	NULL
EBNA2	NULL
is	NULL
initiated	NULL
by	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
regulating	NULL
proteins	NULL
.	NULL

It	NULL
may	NULL
reflect	NULL
a	NULL
regulatory	NULL
cascade	NULL
,	NULL
in	NULL
which	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
given	NULL
gene	NULL
depends	NULL
on	NULL
a	NULL
critical	NULL
threshold	NULL
level	NULL
of	NULL
a	NULL
gene	NULL
product	NULL
synthesized	NULL
earlier	NULL
in	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
EBNA2	NULL
does	NULL
not	NULL
perturb	NULL
the	NULL
physiological	NULL
order	NULL
of	NULL
cell	NULL
cycle	NULL
a	NULL
©	NULL
4	NULL
m	NULL
$	NULL
ngo	NULL
®	NULL
5	NULL
Q	NULL
m	NULL
m	NULL
2	NULL
Oo	NULL
w	NULL
w	NULL
3	NULL
Cyclin	NULL
D2	NULL
``	NULL
~-__	NULL
we	NULL
Cyclin	NULL
E	NULL
L4	NULL
-	NULL
#	NULL
4	NULL
«	NULL
»	NULL
«	NULL
as	NULL
cdk4	NULL
\o	NULL
,	NULL
S	NULL
«	NULL
»	NULL
hs	NULL
cdk2	NULL
__|	NULL
«	NULL
Creare	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Induction	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
E	NULL
and	NULL
edk4	NULL
after	NULL
polyclonal	NULL
stimulation	NULL
of	NULL
primary	NULL
B-cells	NULL
.	NULL

Tonsillar	NULL
B-cells	NULL
were	NULL
activated	NULL
by	NULL
cross-linking	NULL
of	NULL
CD40	NULL
cell	NULL
surface	NULL
molecules	NULL
by	NULL
anti-CD40	NULL
antibody	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interleukin	NULL
4	NULL
for	NULL
2	NULL
days	NULL
or	NULL
by	NULL
treatment	NULL
with	NULL
S.aureus	NULL
for	NULL
2	NULL
days	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
cells	NULL
were	NULL
infected	NULL
by	NULL
EBV	NULL
B95.8	NULL
virus	NULL
and	NULL
harvested	NULL
after	NULL
2	NULL
or	NULL
5	NULL
days	NULL
.	NULL

Expression	NULL
of	NULL
cyclin	NULL
D2	NULL
and	NULL
E	NULL
and	NULL
edk2	NULL
and	NULL
cdk4	NULL
protein	NULL
was	NULL
compared	NULL
with	NULL
expression	NULL
in	NULL
untreated	NULL
B-cells	NULL
.	NULL

progression	NULL
but	NULL
rather	NULL
induces	NULL
B-cell	NULL
activation	NULL
and	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
inducing	NULL
and	NULL
maintaining	NULL
the	NULL
expression	NULL
of	NULL
early	NULL
G	NULL
,	NULL
regulating	NULL
proteins	NULL
.	NULL

Our	NULL
findings	NULL
are	NULL
in	NULL
line	NULL
with	NULL
the	NULL
recent	NULL
report	NULL
of	NULL
Sinclair	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
who	NULL
demonstrated	NULL
induction	NULL
of	NULL
cyclin	NULL
D2	NULL
expression	NULL
and	NULL
entry	NULL
from	NULL
G	NULL
,	NULL
into	NULL
G	NULL
by	NULL
EBNA2Z	NULL
and	NULL
EBNA-LP	NULL
in	NULL
primary	NULL
resting	NULL
B-cells	NULL
.	NULL

Since	NULL
EBNAZ	NULL
is	NULL
a	NULL
pleiotropic	NULL
activator	NULL
of	NULL
the	NULL
other	NULL
EBNAs	NULL
and	NULL
the	NULL
LMPs	NULL
,	NULL
many	NULL
of	NULL
the	NULL
cellular	NULL
events	NULL
observed	NULL
upon	NULL
EBNAZ	NULL
activation	NULL
may	NULL
be	NULL
due	NULL
to	NULL
activation	NULL
of	NULL
viral	NULL
genes	NULL
downstream	NULL
of	NULL
EBNA2	NULL
.	NULL

Considering	NULL
the	NULL
role	NULL
of	NULL
LMP1	NULL
in	NULL
induction	NULL
of	NULL
DNA	NULL
synthesis	NULL
in	NULL
lymphocytes	NULL
and	NULL
transformation	NULL
of	NULL
rodent	NULL
fibroblasts	NULL
,	NULL
it	NULL
will	NULL
be	NULL
particularly	NULL
important	NULL
to	NULL
see	NULL
whether	NULL
constitutive	NULL
expression	NULL
of	NULL
LMPI1	NULL
in	NULL
our	NULL
system	NULL
will	NULL
render	NULL
cell	NULL
proliferation	NULL
independent	NULL
from	NULL
EBNAZ	NULL
activation	NULL
by	NULL
estrogen	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Plasmids	NULL
The	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
was	NULL
fused	NULL
to	NULL
either	NULL
the	NULL
N-	NULL
or	NULL
C-terminal	NULL
end	NULL
of	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
ORF	NULL
)	NULL
of	NULL
EBNA2	NULL
resulting	NULL
in	NULL
plasmid	NULL
ER/EBNA2	NULL
and	NULL
EBNA2/ER	NULL
.	NULL

Both	NULL
plasmids	NULL
had	NULL
the	NULL
overall	NULL
structure	NULL
of	NULL
the	NULL
mini-EBV	NULL
p554	NULL
expressing	NULL
wild-type	NULL
EBNA2	NULL
,	NULL
EBNA-LP	NULL
and	NULL
the	NULL
BHRF1	NULL
open	NULL
reading	NULL
frame	NULL
(	NULL
Hammerschmidt	NULL
and	NULL
Sugden	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
N-terminal	NULL
fusion	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
introducing	NULL
an	NULL
EcoRI	NULL
site	NULL
immediately	NULL
5	NULL
'	NULL
to	NULL
the	NULL
ORF	NULL
of	NULL
EBNA2	NULL
by	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
.	NULL

The	NULL
gene	NULL
fragment	NULL
encoding	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
was	NULL
generated	NULL
by	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
using	NULL
HE14	NULL
(	NULL
Kumar	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
as	NULL
a	NULL
template	NULL
flanked	NULL
by	NULL
EcoRI	NULL
recognition	NULL
sites	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
EcoRI	NULL
site	NULL
in	NULL
front	NULL
of	NULL
the	NULL
ORF	NULL
of	NULL
EBNAZ	NULL
.	NULL

This	NULL
PCR	NULL
fragment	NULL
included	NULL
the	NULL
Kozak	NULL
's	NULL
sequence	NULL
provided	NULL
by	NULL
HE14	NULL
and	NULL
excluded	NULL
the	NULL
stop	NULL
codon	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
.	NULL

The	NULL
C-terminal	NULL
fusion	NULL
construct	NULL
was	NULL
generated	NULL
inserting	NULL
Bg/lI	NULL
and	NULL
EcoRI	NULL
recognition	NULL
sites	NULL
immediately	NULL
before	NULL
the	NULL
stop	NULL
codon	NULL
of	NULL
EBNA2	NULL
by	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
.	NULL

A	NULL
BamHI-EcoRI	NULL
fragment	NULL
of	NULL
HE14	NULL
encoding	NULL
the	NULL
hormone	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
was	NULL
ligated	NULL
into	NULL
the	NULL
Bg/IW/EcoRI	NULL
sites	NULL
at	NULL
the	NULL
end	NULL
of	NULL
EBNA2	NULL
.	NULL

The	NULL
subsequent	NULL
cloning	NULL
steps	NULL
regenerated	NULL
EBV	NULL
strain	NULL
B95.8	NULL
coordinates	NULL
13	NULL
944-54	NULL
364	NULL
(	NULL
according	NULL
to	NULL
Baer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
with	NULL
two	NULL
alterations	NULL
:	NULL
the	NULL
Nof	NULL
!	NULL

repeats	NULL
were	NULL
deleted	NULL
and	NULL
only	NULL
two	NULL
BamHI	NULL
W	NULL
repeats	NULL
inserted	NULL
.	NULL

EBV	NULL
induction	NULL
of	NULL
early	NULL
G	NULL
;	NULL
-regulating	NULL
proteins	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
conditions	NULL
All	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
cell	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
.	NULL

BPL2	NULL
is	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
generated	NULL
by	NULL
infection	NULL
of	NULL
CD19	NULL
enriched	NULL
human	NULL
B-cells	NULL
with	NULL
B95.8	NULL
EBV	NULL
strain	NULL
.	NULL

HHS514	NULL
,	NULL
a	NULL
single	NULL
cell	NULL
clone	NULL
of	NULL
the	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
P3HR1	NULL
(	NULL
Rabson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
,	NULL
was	NULL
diluted	NULL
twice	NULL
a	NULL
week	NULL
1:4	NULL
.	NULL

MRCS	NULL
,	NULL
a	NULL
human	NULL
embryonal	NULL
lung	NULL
fibroblast	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
was	NULL
diluted	NULL
1:2	NULL
twice	NULL
a	NULL
week	NULL
.	NULL

Human	NULL
B-cells	NULL
were	NULL
purified	NULL
from	NULL
tonsils	NULL
by	NULL
generating	NULL
single	NULL
cell	NULL
suspensions	NULL
and	NULL
depletion	NULL
of	NULL
T-cells	NULL
by	NULL
rosetting	NULL
with	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
.	NULL

B-cells	NULL
(	NULL
95	NULL
%	NULL
positive	NULL
for	NULL
the	NULL
pan	NULL
B-cell	NULL
marker	NULL
CD19	NULL
)	NULL
were	NULL
activated	NULL
by	NULL
anti-CD40	NULL
antibody	NULL
(	NULL
mAb89	NULL
;	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

crosslinked	NULL
on	NULL
CD32-transfected	NULL
L-cells	NULL
(	NULL
Peltz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
plus	NULL
interleukin	NULL
4	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
(	NULL
Banchereau	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
or	NULL
by	NULL
S.qureus	NULL
particles	NULL
(	NULL
SAC	NULL
)	NULL
for	NULL
2	NULL
days	NULL
.	NULL

For	NULL
infection	NULL
of	NULL
primary	NULL
B-cells	NULL
with	NULL
EBV	NULL
,	NULL
B-cells	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
or	NULL
5	NULL
days	NULL
with	NULL
the	NULL
supernatant	NULL
of	NULL
the	NULL
marmoset	NULL
cell	NULL
line	NULL
B95.8	NULL
(	NULL
Miller	NULL
and	NULL
Lipman	NULL
,	NULL
1973	NULL
)	NULL
which	NULL
produces	NULL
infectious	NULL
B95.8	NULL
virus	NULL
.	NULL

immunostaining	NULL
of	NULL
proteins	NULL
For	NULL
Western	NULL
blot	NULL
analysis	NULL
cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
25	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
25	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerine	NULL
,	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
mercaptoethanol	NULL
,	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
0.1	NULL
%	NULL
bromphenol	NULL
blue	NULL
)	NULL
and	NULL
sonicated	NULL
.	NULL

Proteins	NULL
were	NULL
separated	NULL
on	NULL
SDS-PAGE	NULL
and	NULL
electroblotted	NULL
onto	NULL
PVDF	NULL
membrane	NULL
(	NULL
Immobilon-P	NULL
,	NULL
Millipore	NULL
)	NULL
.	NULL

Equal	NULL
loading	NULL
of	NULL
the	NULL
gels	NULL
was	NULL
verified	NULL
by	NULL
Ponceau	NULL
red	NULL
staining	NULL
.	NULL

Expression	NULL
of	NULL
protein	NULL
was	NULL
analysed	NULL
using	NULL
the	NULL
following	NULL
antibodies	NULL
:	NULL
polyclonal	NULL
rabbit	NULL
antisera	NULL
specific	NULL
for	NULL
edc2	NULL
,	NULL
edk2	NULL
,	NULL
edk4	NULL
,	NULL
and	NULL
cyclin	NULL
A	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
M.Pagano	NULL
;	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
specific	NULL
for	NULL
E2F-1	NULL
generated	NULL
by	NULL
PJ.-D.	NULL
;	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
cyclin	NULL
E	NULL
and	NULL
cyclin	NULL
D1	NULL
kindly	NULL
provided	NULL
by	NULL
E.Lees	NULL
and	NULL
J.Bartek	NULL
;	NULL
monoclonal	NULL
anti-p53	NULL
(	NULL
DO-1	NULL
)	NULL
,	NULL
rabbit	NULL
polyclonal	NULL
anti-cyclin	NULL
D2	NULL
and	NULL
D3	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
and	NULL
monoclonal	NULL
anti-Rb	NULL
antibody	NULL
(	NULL
Ab-4	NULL
,	NULL
Oncogene	NULL
Science	NULL
Inc.	NULL
)	NULL
;	NULL
monoclonal	NULL
mouse	NULL
anti-MYC	NULL
(	NULL
9E10	NULL
,	NULL
Oncogene	NULL
Science	NULL
Inc.	NULL
)	NULL
;	NULL
anti-LMP1	NULL
(	NULL
CS1-4	NULL
,	NULL
DAKO	NULL
)	NULL
,	NULL
rat	NULL
monoclonal	NULL
anti-EBNAZ	NULL
(	NULL
EBNA2-R3	NULL
,	NULL
Zimber-Strobl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
anti-EBNA1	NULL
(	NULL
EBNA1I-1H4	NULL
,	NULL
Grisser	NULL
er	NULL
al	NULL
.	NULL

,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

Immunoreactive	NULL
proteins	NULL
were	NULL
detected	NULL
by	NULL
peroxidase	NULL
coupled	NULL
secondary	NULL
antibodies	NULL
and	NULL
enhanced	NULL
chemiluminiscence	NULL
(	NULL
ECL	NULL
)	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Transformation	NULL
of	NULL
primary	NULL
B-cells	NULL
by	NULL
conditional	NULL
virus	NULL
HHS14	NULL
cells	NULL
(	NULL
1X	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
pCMV-BZLFI	NULL
and	NULL
10	NULL
ug	NULL
EBNAZ	NULL
,	NULL
ER/EBNA2	NULL
or	NULL
EBNA2/ER	NULL
expression	NULL
mini-EBV	NULL
plasmids	NULL
by	NULL
electroporation	NULL
using	NULL
the	NULL
Bio-Rad	NULL
gene	NULL
pulser	NULL
at	NULL
960	NULL
uF	NULL
,	NULL
and	NULL
250	NULL
V	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
250	NULL
ul	NULL
RPMI1640	NULL
cell	NULL
culture	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

After	NULL
electroporation	NULL
cells	NULL
were	NULL
kept	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
10	NULL
ml	NULL
RPMI1640	NULL
cell	NULL
culture	NULL
medium	NULL
.	NULL

After	NULL
4	NULL
days	NULL
the	NULL
supernatant	NULL
of	NULL
the	NULL
transfected	NULL
cell	NULL
was	NULL
harvested	NULL
and	NULL
filtered	NULL
through	NULL
a	NULL
0.45	NULL
pum	NULL
sterile	NULL
filter	NULL
.	NULL

Ficoll-purified	NULL
primary	NULL
cord	NULL
blood	NULL
lymphocytes	NULL
or	NULL
CD19-positive	NULL
enriched	NULL
peripheral	NULL
B-cells	NULL
were	NULL
infected	NULL
with	NULL
the	NULL
filtered	NULL
supernatants	NULL
by	NULL
overnight	NULL
incubation	NULL
.	NULL

Infected	NULL
cells	NULL
,	NULL
seeded	NULL
in	NULL
96	NULL
well	NULL
flat	NULL
bottom	NULL
plates	NULL
(	NULL
50	NULL
000	NULL
cells/well	NULL
)	NULL
and	NULL
cultivated	NULL
on	NULL
irradiated	NULL
MRCS	NULL
fibroblast	NULL
feeder	NULL
layers	NULL
(	NULL
5000	NULL
rad	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
estrogen	NULL
(	NULL
1	NULL
uM	NULL
,	NULL
B-estradiol	NULL
)	NULL
,	NULL
gave	NULL
rise	NULL
to	NULL
cell	NULL
lines	NULL
after	NULL
4-6	NULL
weeks	NULL
.	NULL

Established	NULL
LCLs	NULL
were	NULL
routinely	NULL
grown	NULL
in	NULL
phenol	NULL
red	NULL
free	NULL
RPMI1640	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
estrogen	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
depleted	NULL
from	NULL
endogenous	NULL
estrogen	NULL
by	NULL
dextrane	NULL
treated	NULL
charcoal	NULL
.	NULL

MTT	NULL
assay	NULL
Cells	NULL
(	NULL
30	NULL
000	NULL
)	NULL
were	NULL
seeded	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
cell	NULL
culture	NULL
medium	NULL
.	NULL

After	NULL
incubation	NULL
with	NULL
MTT	NULL
[	NULL
3-	NULL
(	NULL
4,5-dimethylthiazol-2-yl	NULL
)	NULL
-2	NULL
2,5-diphenyl	NULL
tetra-zolium	NULL
bromide	NULL
;	NULL
0.5	NULL
mg/m	NULL
!	NULL
)	NULL

for	NULL
5	NULL
h	NULL
,	NULL
MTT	NULL
conversion	NULL
,	NULL
which	NULL
correlates	NULL
to	NULL
the	NULL
number	NULL
of	NULL
living	NULL
cells	NULL
in	NULL
the	NULL
assay	NULL
,	NULL
was	NULL
determined	NULL
in	NULL
the	NULL
ELISA	NULL
reader	NULL
as	NULL
described	NULL
by	NULL
Mosmann	NULL
(	NULL
1983	NULL
)	NULL
.	NULL

RHJ	NULL
}	NULL
thymidine	NULL
incorporation	NULL
For	NULL
determination	NULL
of	NULL
DNA	NULL
synthesis	NULL
30	NULL
000	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
100	NULL
ul	NULL
per	NULL
well	NULL
on	NULL
day	NULL
0	NULL
and	NULL
kept	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
estrogen	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
.	NULL

[	NULL
°HIthymidine	NULL
(	NULL
0.5	NULL
Ci	NULL
)	NULL
was	NULL
added	NULL
per	NULL
well	NULL
for	NULL
3	NULL
h	NULL
and	NULL
incorporation	NULL
of	NULL
radioactivity	NULL
was	NULL
determined	NULL
in	NULL
harvested	NULL
cells	NULL
.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cellular	NULL
DNA	NULL
content	NULL
Cell	NULL
cultures	NULL
were	NULL
incubated	NULL
for	NULL
60	NULL
min	NULL
with	NULL
Hoechst	NULL
33342	NULL
(	NULL
5	NULL
ug/ml	NULL
,	NULL
37°C	NULL
,	NULL
6	NULL
%	NULL
CO	NULL
;	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
content	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
FACS	NULL
star	NULL
plus	NULL
(	NULL
Becton	NULL
and	NULL
Dickinson	NULL
)	NULL
using	NULL
an	NULL
excitation	NULL
wavelength	NULL
of	NULL
365	NULL
nm	NULL
.	NULL

Apoptotic	NULL
cells	NULL
were	NULL
discriminated	NULL
by	NULL
their	NULL
differential	NULL
fluorescence	NULL
emission	NULL
spectra	NULL
at	NULL
>	NULL
550	NULL
nm	NULL
versus	NULL
424	NULL
+	NULL
44	NULL
nm	NULL
of	NULL
viable	NULL
cells	NULL
after	NULL
95	NULL
B.Kempkes	NULL
et	NULL
al	NULL
.	NULL

Hoechst	NULL
33342	NULL
staining	NULL
(	NULL
Ellwart	NULL
and	NULL
Dormer	NULL
,	NULL
1990	NULL
;	NULL
Ormerod	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
identified	NULL
and	NULL
excluded	NULL
from	NULL
the	NULL
analyses	NULL
by	NULL
propidium	NULL
iodide	NULL
uptake	NULL
added	NULL
10	NULL
min	NULL
before	NULL
measurement	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

DNA	NULL
content	NULL
was	NULL
analysed	NULL
using	NULL
the	NULL
Multicycle	NULL
program	NULL
(	NULL
Phoenix	NULL
)	NULL
.	NULL

in	NULL
situ	NULL
hybridization	NULL
of	NULL
interphase	NULL
nuclei	NULL
Isolation	NULL
of	NULL
cellular	NULL
nuclei	NULL
and	NULL
in	NULL
site	NULL
suppression	NULL
hybridization	NULL
using	NULL
the	NULL
Cot-1	NULL
DNA	NULL
fraction	NULL
as	NULL
competitor	NULL
was	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Lichter	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
cosmid	NULL
probe	NULL
encompassing	NULL
the	NULL
IgA	NULL
locus	NULL
was	NULL
labelled	NULL
with	NULL
biotin-16-dUTP	NULL
by	NULL
random	NULL
priming	NULL
followed	NULL
by	NULL
sonification	NULL
(	NULL
Combriato	NULL
and	NULL
Klobeck	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

Hybridization	NULL
of	NULL
the	NULL
IgA	NULL
probe	NULL
was	NULL
detected	NULL
by	NULL
avidin	NULL
FITC	NULL
.	NULL

A	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
centromere	NULL
of	NULL
chromosome	NULL
17	NULL
was	NULL
labelled	NULL
with	NULL
digoxigenin-11-dUTP	NULL
by	NULL
PCR	NULL
(	NULL
Selig	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Hybridization	NULL
was	NULL
revealed	NULL
by	NULL
incubation	NULL
with	NULL
anti-digoxigenin	NULL
antibodies	NULL
coupled	NULL
with	NULL
rhodamine	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Specimens	NULL
were	NULL
analysed	NULL
by	NULL
conventional	NULL
epi-fluorescence	NULL
using	NULL
a	NULL
Zeiss	NULL
microscope	NULL
.	NULL

Pictures	NULL
were	NULL
recorded	NULL
with	NULL
a	NULL
CCD	NULL
camera	NULL
(	NULL
Kappa	NULL
Gottingen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Acknowledgements	NULL
We	NULL
thank	NULL
P.Chambon	NULL
for	NULL
the	NULL
probe	NULL
specific	NULL
for	NULL
the	NULL
hormone	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
estrogen	NULL
receptor	NULL
(	NULL
HE14	NULL
)	NULL
,	NULL
M.Pagano	NULL
for	NULL
the	NULL
anti-cdc2	NULL
,	NULL
-edk2	NULL
,	NULL
and	NULL
-cdk4	NULL
antibodies	NULL
and	NULL
FRousset	NULL
and	NULL
J.Banchereau	NULL
for	NULL
help	NULL
with	NULL
the	NULL
CD40	NULL
system	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Die	NULL
Deutsche	NULL
Forschungsgemein-schaft	NULL
and	NULL
Fonds	NULL
der	NULL
Chemischen	NULL
Industrie	NULL
.	NULL

H.-J.D	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
and	NULL
PJ.-D.	NULL
by	NULL
the	NULL
Human	NULL
Frontiers	NULL
Science	NULL
Program	NULL
Organization	NULL
.	NULL

References	NULL
Abbot	NULL
,	NULL
S.D	NULL
.	NULL

,	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
Cadwallader	NULL
,	NULL
K.	NULL
,	NULL
Ricksten	NULL
,	NULL
A.	NULL
,	NULL
Gordon	NULL
,	NULL
J.	NULL
,	NULL
Wang	NULL
.	NULL

,	NULL
F.	NULL
,	NULL
Rymo	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Rickinson	NULL
,	NULL
A.B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
2126-2134	NULL
.	NULL

Akiyama	NULL
,	NULL
N	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

,	NULL
54	NULL
,	NULL
377-379	NULL
.	NULL

Allday	NULL
,	NULL
M.J.	NULL
,	NULL
Crawford	NULL
,	NULL
D.H	NULL
.	NULL

and	NULL
Griffin	NULL
,	NULL
B.E	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Gen	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
70	NULL
,	NULL
1755-1764	NULL
.	NULL

Baer	NULL
,	NULL
R	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Nature	NULL
,	NULL
310	NULL
,	NULL
207-211	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
De-Paoli	NULL
,	NULL
P.	NULL
,	NULL
Valle	NULL
,	NULL
A.	NULL
,	NULL
Garcia	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Rousset	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
,	NULL
251	NULL
,	NULL
70-72	NULL
.	NULL

Burk,0	NULL
.	NULL

and	NULL
Klempnauer	NULL
,	NULL
K.H	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
3713-3719	NULL
.	NULL

Calender	NULL
,	NULL
A.	NULL
,	NULL
Billaud	NULL
,	NULL
M.	NULL
,	NULL
Aubry	NULL
,	NULL
J.P.	NULL
,	NULL
Banchereau	NULL
,	NULL
J.	NULL
,	NULL
Vuillaume	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Lenoir	NULL
,	NULL
G.M	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
8060-8064	NULL
.	NULL

Chan	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Stein	NULL
,	NULL
L.D	NULL
.	NULL

,	NULL
Dosch	NULL
,	NULL
H.M	NULL
.	NULL

and	NULL
Sigal	NULL
,	NULL
N.H	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
136	NULL
,	NULL
106-112	NULL
.	NULL

Cohen	NULL
,	NULL
J.I	NULL
.	NULL

,	NULL
Wang.F	NULL
.	NULL

,	NULL
Mannick	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Kieff	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
9558-9562	NULL
.	NULL

Combriato	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Klobeck	NULL
,	NULL
H.G	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
21	NULL
,	NULL
1513-1522	NULL
.	NULL

Cordier	NULL
,	NULL
M.	NULL
,	NULL
-	NULL
Calender	NULL
,	NULL
A.	NULL
,	NULL
-	NULL
Billaud	NULL
,	NULL
M.	NULL
,	NULL
-	NULL
Zimber	NULL
,	NULL
U.	NULL
,	NULL
-	NULL
Rousselet	NULL
,	NULL
G.	NULL
,	NULL
Pavlish	NULL
,	NULL
O.	NULL
,	NULL
Banchereau	NULL
,	NULL
J.	NULL
,	NULL
Tursz	NULL
,	NULL
T.	NULL
,	NULL
Bornkamm	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Lenoir	NULL
,	NULL
G.M	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
1002-1013	NULL
.	NULL

Eilers	NULL
,	NULL
M.	NULL
,	NULL
Picard	NULL
,	NULL
D.	NULL
,	NULL
Yamamoto	NULL
,	NULL
K.R	NULL
.	NULL

and	NULL
Bishop	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
340	NULL
,	NULL
66-68	NULL
.	NULL

Ellwart	NULL
,	NULL
J.W	NULL
.	NULL

and	NULL
Dormer	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cytometry	NULL
,	NULL
11	NULL
,	NULL
239-243	NULL
.	NULL

Fahraeus	NULL
,	NULL
R.	NULL
,	NULL
Jansson	NULL
,	NULL
A.	NULL
,	NULL
Ricksten	NULL
,	NULL
A.	NULL
,	NULL
Sjoblom	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Rymo	NULL
,	NULL
L	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
$	NULL
7	NULL
,	NULL
7390-7394	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
and	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
55	NULL
,	NULL
427-433	NULL
.	NULL

Hammerschmidt	NULL
,	NULL
W.	NULL
and	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
340	NULL
,	NULL
393-397	NULL
.	NULL

Helin	NULL
,	NULL
K.	NULL
,	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Dyson	NULL
,	NULL
N.	NULL
,	NULL
Harlow	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Fattaey	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
,	NULL
70	NULL
,	NULL
337-350	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
Ling	NULL
,	NULL
P.D	NULL
.	NULL

,	NULL
Hayward	NULL
,	NULL
S.D	NULL
.	NULL

and	NULL
Peterson	NULL
,	NULL
M.G	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Science	NULL
,	NULL
265	NULL
,	NULL
92-95	NULL
.	NULL

Hiebert	NULL
,	NULL
S.W	NULL
.	NULL

,	NULL
Lipp.M	NULL
.	NULL

and	NULL
Nevins	NULL
,	NULL
J.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
3594-3598	NULL
.	NULL

Hutt-Fletcher	NULL
,	NULL
L.M	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
61	NULL
,	NULL
774-781	NULL
.	NULL

Kaye	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Izumi	NULL
,	NULL
K.M	NULL
.	NULL

and	NULL
Kieff	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
9150-9154	NULL
.	NULL

Kieff	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Liebowitz	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
In	NULL
Fields	NULL
,	NULL
B.N	NULL
.	NULL

,	NULL
Knipe	NULL
,	NULL
D.N	NULL
.	NULL

,	NULL
Chanock	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
Hirsch	NULL
,	NULL
M.S	NULL
.	NULL

,	NULL
Melnick	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
Monath	NULL
,	NULL
T.P	NULL
.	NULL

and	NULL
Roizman	NULL
,	NULL
B	NULL
.	NULL

(	NULL
eds	NULL
)	NULL
,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
,	NULL
pp	NULL
.	NULL

1889-1920	NULL
.	NULL

_	NULL
Knutson	NULL
,	NULL
J.C	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
2530-2536	NULL
.	NULL

Kumar	NULL
,	NULL
V.	NULL
,	NULL
Green	NULL
,	NULL
S.	NULL
,	NULL
Staub	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Chambon	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
5	NULL
,	NULL
2231-2236	NULL
.	NULL

Lichter	NULL
,	NULL
P.	NULL
,	NULL
Tang	NULL
,	NULL
C.J	NULL
.	NULL

,	NULL
Call	NULL
,	NULL
K.	NULL
,	NULL
Hermanson	NULL
,	NULL
G.	NULL
,	NULL
Evans	NULL
,	NULL
G.A	NULL
.	NULL

,	NULL
Housman	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Ward	NULL
,	NULL
D.C	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
,	NULL
247	NULL
,	NULL
64-69	NULL
.	NULL

96	NULL
Ling	NULL
,	NULL
P.D	NULL
.	NULL

,	NULL
Rawlins	NULL
,	NULL
D.R	NULL
.	NULL

and	NULL
Hayward	NULL
,	NULL
S.D	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
9237-9241	NULL
.	NULL

Matsunami	NULL
,	NULL
N.	NULL
,	NULL
Hamaguchi	NULL
,	NULL
Y.	NULL
,	NULL
Yamamoto	NULL
,	NULL
Y.	NULL
,	NULL
Kuze	NULL
,	NULL
K.	NULL
,	NULL
Kangawa	NULL
,	NULL
K.	NULL
,	NULL
Matsuo	NULL
,	NULL
H.	NULL
,	NULL
Kawaichi	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Honjo	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
342	NULL
,	NULL
934-937	NULL
.	NULL

Matsushime	NULL
,	NULL
H.	NULL
,	NULL
Quelle	NULL
,	NULL
D.	NULL
,	NULL
Shurtleff	NULL
,	NULL
S.A.	NULL
,	NULL
Shibuya	NULL
,	NULL
M.	NULL
,	NULL
Sherr	NULL
,	NULL
C.J	NULL
.	NULL

and	NULL
Kato	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
14	NULL
,	NULL
2066-2076	NULL
.	NULL

Miller	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
Fields	NULL
,	NULL
B.N	NULL
.	NULL

,	NULL
Knipe	NULL
,	NULL
D.N	NULL
.	NULL

,	NULL
Chanock	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
Hirsch	NULL
,	NULL
M.S	NULL
.	NULL

,	NULL
Melnick	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
Monath	NULL
,	NULL
T.P	NULL
.	NULL

and	NULL
Roizman	NULL
,	NULL
B	NULL
.	NULL

(	NULL
eds	NULL
)	NULL
,	NULL
Virology	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
,	NULL
pp	NULL
.	NULL

1921-1985	NULL
.	NULL

Miller	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Lipman	NULL
,	NULL
M.	NULL
(	NULL
1973	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
70	NULL
,	NULL
190-194	NULL
.	NULL

Mosmann	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
,	NULL
65	NULL
,	NULL
55-63	NULL
.	NULL

Mueller-Lantzsch	NULL
,	NULL
N.	NULL
,	NULL
Lenoir	NULL
,	NULL
G.M	NULL
.	NULL

,	NULL
Sauter	NULL
,	NULL
M.	NULL
,	NULL
Takaki	NULL
,	NULL
K.	NULL
,	NULL
Bechet	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Kuklik-Roos	NULL
,	NULL
C.	NULL
,	NULL
Wunderlich	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Bomkamm	NULL
,	NULL
G.W	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
4	NULL
,	NULL
1805-1811	NULL
.	NULL

Ormerod	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
Collins	NULL
,	NULL
M.K	NULL
.	NULL

,	NULL
Rodriguez	NULL
Tarduchy	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Robertson	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
,	NULL
153	NULL
,	NULL
57-65	NULL
.	NULL

Pagano.M	NULL
.	NULL

,	NULL
Pepperkok	NULL
,	NULL
R.	NULL
,	NULL
Verde	NULL
,	NULL
F.	NULL
,	NULL
Ansorge	NULL
,	NULL
W.	NULL
and	NULL
Dractta	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
961-971	NULL
.	NULL

Palmero	NULL
,	NULL
I.	NULL
,	NULL
Holder	NULL
,	NULL
A.	NULL
,	NULL
Sinclair	NULL
,	NULL
A.J	NULL
.	NULL

,	NULL
Dickson	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Peters	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Oncogene	NULL
,	NULL
8	NULL
,	NULL
1049-1054	NULL
.	NULL

Peltz	NULL
,	NULL
G.A	NULL
.	NULL

,	NULL
Trounstine	NULL
,	NULL
M.L	NULL
.	NULL

and	NULL
Moore	NULL
,	NULL
K.W	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
141	NULL
,	NULL
1891-1896	NULL
.	NULL

Peng	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Lundgren	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Oncogene	NULL
,	NULL
7	NULL
,	NULL
1775-1782	NULL
.	NULL

Picard	NULL
,	NULL
D.	NULL
,	NULL
Salser	NULL
,	NULL
S8.J	NULL
.	NULL

and	NULL
Yamamoto	NULL
,	NULL
K.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cel/	NULL
,	NULL
54	NULL
,	NULL
1073-1080	NULL
.	NULL

Pines	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
18	NULL
,	NULL
195-197	NULL
.	NULL

Rabson	NULL
,	NULL
M.	NULL
,	NULL
Gradoville	NULL
,	NULL
L.	NULL
,	NULL
Heston	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Miller	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
44	NULL
,	NULL
834-844	NULL
.	NULL

Rimokh	NULL
,	NULL
R	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Blood	NULL
,	NULL
81	NULL
,	NULL
3063-3067	NULL
.	NULL

Rogers	NULL
,	NULL
R.P	NULL
.	NULL

,	NULL
Strominger	NULL
,	NULL
J.L	NULL
.	NULL

and	NULL
Speck	NULL
,	NULL
S.H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Adv	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
58	NULL
,	NULL
1-26	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
,	NULL
Howe	NULL
,	NULL
J.G	NULL
.	NULL

,	NULL
Speck	NULL
,	NULL
S.H	NULL
.	NULL

and	NULL
Miller	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
63	NULL
,	NULL
1531-1539	NULL
.	NULL

Rooney	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
Brimmell	NULL
,	NULL
M.	NULL
,	NULL
Buschle	NULL
,	NULL
M.	NULL
,	NULL
Allan	NULL
,	NULL
G.	NULL
,	NULL
Farrell	NULL
,	NULL
PJ	NULL
.	NULL

and	NULL
Kolman	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
66	NULL
,	NULL
496-504	NULL
.	NULL

Selig	NULL
,	NULL
S.	NULL
,	NULL
Okumura	NULL
,	NULL
K.	NULL
,	NULL
Ward	NULL
,	NULL
D.C	NULL
.	NULL

and	NULL
Cedar	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
11	NULL
,	NULL
1217-1225	NULL
.	NULL

Sherr	NULL
,	NULL
C.J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
,	NULL
73	NULL
,	NULL
1059-1065	NULL
.	NULL

Sinclair	NULL
,	NULL
A.	NULL
,	NULL
Palmero	NULL
,	NULL
L	NULL
,	NULL
Peters.G	NULL
.	NULL

and	NULL
Farrell	NULL
,	NULL
PJ	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
3321-3328	NULL
.	NULL

Spitkovsky	NULL
,	NULL
D	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
68	NULL
,	NULL
2206-2214	NULL
.	NULL

Sung	NULL
,	NULL
N.S	NULL
.	NULL

,	NULL
Kenney	NULL
,	NULL
S.	NULL
,	NULL
Gutsch	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Pagano	NULL
,	NULL
J.S	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
65	NULL
,	NULL
2164-2169	NULL
.	NULL

Thalmeier	NULL
,	NULL
K.	NULL
,	NULL
Synovzik	NULL
,	NULL
H.	NULL
,	NULL
Mertz	NULL
,	NULL
R.	NULL
,	NULL
Winnacker	NULL
,	NULL
E.L	NULL
.	NULL

and	NULL
Lipp	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
3	NULL
,	NULL
527-536	NULL
.	NULL

Tomkinson	NULL
,	NULL
B.	NULL
,	NULL
Robertson	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Kieff	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
67	NULL
,	NULL
2014-2025	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
,	NULL
Liebowitz	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Kieff	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
,	NULL
43	NULL
,	NULL
831-840	NULL
.	NULL

Wang	NULL
,	NULL
F.	NULL
,	NULL
-	NULL
Gregory	NULL
,	NULL
C.D	NULL
.	NULL

,	NULL
-	NULL
Rowe	NULL
,	NULL
M.	NULL
,	NULL
-	NULL
Rickinson	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
-	NULL
Wang	NULL
,	NULL
D.	NULL
,	NULL
Birkenbach	NULL
,	NULL
M.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Kishimoto	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Kieff	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
3452-3456	NULL
.	NULL

Yates	NULL
,	NULL
J.	NULL
,	NULL
Warren	NULL
,	NULL
N.	NULL
,	NULL
Reisman	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Sugden	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
81	NULL
,	NULL
3806-3810	NULL
.	NULL

Zimber-Strobl	NULL
,	NULL
U.	NULL
,	NULL
Kremmer	NULL
,	NULL
E.	NULL
,	NULL
Grasser	NULL
,	NULL
F.	NULL
,	NULL
Marschall	NULL
,	NULL
G.	NULL
,	NULL
Laux	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Bornkamm	NULL
,	NULL
G.W	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
167-175	NULL
.	NULL

Zimber-Strobl	NULL
,	NULL
U.	NULL
,	NULL
Suentzenich	NULL
,	NULL
K.0	NULL
.	NULL

,	NULL
Laux	NULL
,	NULL
G.	NULL
,	NULL
Eick	NULL
,	NULL
D.	NULL
,	NULL
Cordier	NULL
,	NULL
M.	NULL
,	NULL
Calender	NULL
,	NULL
A.	NULL
,	NULL
Billaud	NULL
,	NULL
M.	NULL
,	NULL
Lenoir	NULL
,	NULL
G.M	NULL
.	NULL

and	NULL
Bornkamm	NULL
,	NULL
G.W	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
65	NULL
,	NULL
415-423	NULL
.	NULL

Received	NULL
on	NULL
August	NULL
1	NULL
,	NULL
1994	NULL
;	NULL
revised	NULL
on	NULL
September	NULL
29	NULL
,	NULL
1994	NULL

